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Xanthone-1,2,3-triazole dyads have been synthesized by two
different approaches, both starting from novel (E)-2-(4-aryl-
but-1-en-3-yn-1-yl)chromones, prepared through a base-cat-
alyzed aldol reaction of 2-methylchromone and arylpropar-
gyl aldehydes. In the first method, the xanthone moiety is
built by Diels–Alder reaction of the referred unsaturated
chromones with N-methylmaleimide under microwave irra-
diation, followed by oxidation of the obtained adducts with
Introduction
Xanthones or 9H-xanthen-9-ones are one of the most
important classes of naturally occurring oxygenated hetero-
cyclic compounds possessing a dibenzo-γ-pyrone frame-
work. The parent xanthone has not been reported as a nat-
ural product.[1] However, in 2002 Oldenburg et al. described
the occurrence of this xanthone in crude oils from offshore
Norway. The authors suggest that this product can be
formed by oxidation of xanthene in the reservoir or ob-
tained by geosynthesis from aromatic precursors.[2] Natural
xanthones often appear as highly substituted derivatives,
bearing methoxy, hydroxy, alkyl, isopentenyl and glycosyl
groups in their monomeric, dimeric, polycyclic or
xanthonolignoide forms.[3] In the past few years, a great
number of studies have emphasized the biological and phar-
macological properties of both natural and synthetic
xanthones,[4] including anti-inflammatory,[5] cancer chemo-
preventive,[6] antimalarial,[7] and radical scavenging activi-
ties.[8] The inhibitory activities of these agents against en-
zymes such as cyclooxygenase and cholinesterase have also
been reported.[4,9]
Likewise, among the nitrogen heterocycles, triazoles have
particular relevance due to their application in several re-
search fields such as biochemistry, pharmaceutical and ma-
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DDQ, whereas the 1,2,3-triazole ring results from the cyclo-
addition reaction of the acetylene moiety with sodium azide.
The second strategy first involves the cycloaddition reaction
with sodium azide to provide the 1,2,3-triazole ring, followed
by methylation of the triazole NH group prior to Diels–Alder
reaction with N-methylmaleimide. The last step in this syn-
thesis of novel xanthone-1,2,3-triazole dyads entails oxid-
ation of the cycloadducts with DDQ.
terial science. Triazoles have been used as drugs,[10] and are
known to possess anti-HIV-type I protease,[11] anti-hyper-
glycemic,[12] and antimicrobial activities, among others.[13]
In terms of medicinal chemistry, it has been demonstrated
that 1,4- and 1,5-disubstituted 1,2,3-triazoles can partici-
pate in important binding interactions with biological tar-
gets, maintaining a good pharmacokinetic profile.[14] In ad-
dition, they are commercially used as anticorrosive
agents,[15] agrochemicals,[16] photostabilizers and dyes.[17]
Considering the biological properties exhibited by these
two classes of heterocycles, the development of new pro-
duction methods for xanthone-1,2,3-triazole dyads aimed
specifically at developing potentially improved therapeutic
agents is a high priority. This idea was recently exemplified
by a study carried out by Zou et al. in which xanthones
bearing a 1,4-disubstituted-1,2,3-triazole moiety showed
promising antitumor activity.[18] Another study indicated
that 3,6-dihydroxyxanthone, known as a good fluorophore,
increased its fluorescence upon triazole formation.[19] With
this rational in mind, we designed and synthesized novel
chromone derivatives to be used as building blocks in the
synthesis of xanthone-1,2,3-triazole dyads. The first reports
dealing with the reactivity of chromone derivatives in Diels–
Alder (DA) reactions en route to xanthone derivatives have
been summarized by our group in 1993.[20] At that time,
xanthene adducts were not characterized and were assumed
to have the expected 1,2,3,9a-tetrahydroxanthene structure.
Subsequently, other studies revealed that the products
formed were, in fact, 1,2,3,4-tetrahydroxanthenes.[21] In
2000, 2-vinylchromones were also used as starting materials
in [4 + 2] cycloaddition reactions with enamines for the syn-
thesis of new xanthone derivatives.[22] More recently, studies
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on DA reactions of 3-styrylchromones under microwave ir-
radiation in solvent-free conditions resulted in a new strat-
egy for the synthesis of novel xanthones.[23] In 2009, 2- and
3-styrylchromones were used in cyclization reactions to af-
ford new polyhydroxylated 2,3-diarylxanthones.[24] Follow-
ing the previously described studies, 2-(4-arylbuta-1,3-dien-
1-yl)chromones underwent electrocyclization and oxidation
processes in order to prepare 1-arylxanthones.[25] In this pa-
per, we disclose our synthesis of new chromone derivatives,
2-(4-arylbut-1-en-3-yn-1-yl)chromones 4a–d, which were
further used as synthons to generate new xanthone-1,2,3-
triazole dyads. Such chromones 4a–d possess two unsatu-
rated systems (a diene and an alkyne) anticipated to display
different reactivities in cycloaddition reactions. Moreover,
these new chromones can participate in two consecutive
types of cycloaddition reactions; namely, DA and Huisgen
azide–alkyne 1,3-dipolar cycloadditions (“click chemistry”).
Herein, we present two different synthetic strategies en-
abling facile access to new chromone-1,2,3-triazole deriva-
tives as well as xanthone-1,2,3-triazole dyads.
Results and Discussion
Syntheses
Novel (E)-2-(4-arylbut-1-en-3-yn-1-yl)chromones 4a–d
were obtained in moderate to good yields (52–80%) using
a base-catalyzed aldol reaction of 2-methylchromone 1 with
arylpropargyl aldehydes 3a–d in ethanolic solutions
(Scheme 1).[25] The required starting material 2-methyl-
chromone (1) was prepared by a three-step Baker–Venkata-
raman sequence in good overall yields.[26] Since arylprop-
argyl aldehydes 3b–d are not commercially available, we
generated them using a two-step approach: i) palladium-
catalyzed cross-coupling reaction of aryl iodides with prop-
argyl alcohol[27] in order to prepare the corresponding aryl-
propargyl alcohols 2b–d, in good yields (79–95%); ii) oxid-
ation of the arylpropargyl alcohols 2b–d with activated
MnO2 to afford desired arylpropargyl aldehydes 3b–d, in
excellent yields (86–97%). The first step of this methodol-
Scheme 1. Synthesis of (E)-2-(4-arylbut-1-en-3-yn-1-yl)chromones 4a–d.
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ogy was slightly improved by using toluene as solvent in the
presence of 1.5 equiv. piperidine instead of in neat dieth-
ylamine (Scheme 1).
In our first approach to the target xanthone-1,2,3-tri-
azole dyads, newly synthesized chromones 4a–d were used
as dienes in DA reactions with the poor dienophile N-
methyl-maleimide (Scheme 2). The structure of each conju-
gated diene suggests that it could not be very reactive due
to extended electron delocalization. Thus, we tried highly
energetic reaction conditions using 1,2,4-trichlorobenzene
(TCB) under refluxing conditions (Table 1, Entry 1). No
DA reaction took place and after a reaction time of 7 d
only degradation of the starting material was observed
when using two different derivatives 4a and 4c (Table 1, En-
tries 1 and 2). Slightly less energetic conditions (DMF at
reflux for 48 h) once again failed to produce any DA reac-
tion despite the inclusion of the Lewis acid Sc(OTf)3
(Table 1, Entries 3 and 4). The failure of the normal (or
“typical”) electron demand DA reaction to produce mean-
ingful results inspired us to attempt the reaction using an
electron rich dienophile (dihydropyran) in neat conditions
(Table 1, Entry 5). This DA reaction also failed to take
place; we postulate that this is a consequence of the low
reaction temperature imposed by the low boiling point of
dihydropyran.
On the basis of previous findings by our group[23,28] we
performed the DA reaction under microwave irradiation
(multimode apparatus) conditions. Several experiments
were carried out in which reaction times, solvent, Lewis
acids, amounts of dienophile and microwave potencies were
varied (Table 1, Entries 6–15). The best results were
achieved in a reaction time of 20 min, at 160 °C using a few
drops of DMF as solvent (Table 1, Entries 6, 16–18). DA
adducts 5a–d were obtained in low yields (20–30%) al-
though it is worth noting that a significant amount of start-
ing chromone could be readily recovered (65–70%). Thus,
the poor yields can be explained by the competition of the
retro-DA reaction, which is often promoted at such tem-
peratures.[29] When the reaction of 4c with N-methylmale-
imide was performed under the optimized conditions
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Scheme 2. Strategy for the synthesis of xanthone-1,2,3-triazole dyads 7a–d.
Table 1. Optimization of the Diels–Alder reaction conditions for the synthesis of 4-(arylethynyl)-2-methyl/phenyl-3a,4,5,11b-tetra-
hydrochromeno[3,2-e]isoindole-1,3,11-triones 5a–d.
Entry Heating method Reactant Solvent Time T [°C] Catalyst Isolated yield [%] Recovered starting material [%]
1 oil bath 4a 1,2,4-TCB 7 d reflux – no reaction –
2 oil bath 4c 1,2,4-TCB 7 d reflux – no reaction –
3 oil bath 4c DMF 48 h reflux Sc(OTf)3 no reaction –
4 oil bath 4c DMF 48 h reflux – no reaction –
5 oil bath 4b –[e] 24 h 80 – no reaction –
6 MW (800 W) 4c DMF[a] 40 min 160 – 30 67
7 MW (800 W) 4c DMF[a] 40 min 160 AlCl3 30 65
8 MW (800 W) 4c DMF[a] 40 min 160 Sc(OTf)3 30 66
9 MW (800 W) 4c DMF[a] 20 min 160 – 30 68
10 MW (800 W) 4c DMF[a] 10 min 160 – 14 76
11 MW (800 W) 4c DMF[c] 40 min 160 – no reaction –
12 MW (800 W) 4c NMP[a] 40 min 160 – no reaction –
13 MW (600 W) 4c NMP[a] 40 min 150 – 5 70
14 MW (600 W) 4c NMP[b] 40 min 150 – no reaction –
15 MW (600 W) 4c DMF[b] 40 min 150 – no reaction –
16 MW (800 W) 4a DMF[a] 20 min 160 – 28 67
17 MW (800 W) 4b DMF[a] 20 min 160 – 20 72
18 MW (800 W) 4d DMF[a] 20 min 160 – 30 66
19 MW (800 W) 4b DMF[d] 40 min 160 – 14 10
[a] A few drops of DMF and 5 equiv. of N-methylmaleimide. [b] 5 mL of solvent and 10 equiv. N-methylmaleimide. [c] Dimethyl acetylene-
dicarboxylate. [d] N-phenylmaleimide. [e] Dihydropyran.
(160 °C, using a few drops of DMF as solvent) for 10 min
cycloadduct 5c was isolated in 14% yield; reaction times of
20 and 40 min afforded the same yield (30%) (Table 1, En-
tries 6, 9 and 10). At lower reaction temperature (100 °C),
cycloadduct 5c was obtained in 1% yield and 80% of the
starting material was recovered.
A single attempt to test N-phenylmaleimide as the
dienophile led to no improvements in the DA reaction and
led to only a 14% yield of cycloadduct 5e and 10% re-
covered starting material (Table 1, Entry 19, Scheme 2). The
DA reaction has also been studied using monomode micro-
wave equipment in solvent-free conditions. As an example,
chromone 4c was used in three experiments performed at 5,
10 and 20 min of irradiation at 200 °C. The best results
(31%) were not significantly better than those obtained un-
der the multimode microwave conditions (30%). However,
it was possible to achieve similar results in shorter reaction
times (10 min). Thus, after 5 min of irradiation it was pos-
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sible to isolate 5c in 23% yield; with 10 or 20 min of irradia-
tion the yields increased to 31%. Applying these optimized
conditions to the other derivatives, we can conclude that
the yields were slightly improved (36–45%) using this envi-
ronmentally friendlier technique since the reaction occurs
in solvent-free conditions and in a shorter reaction time.
The next step of our first strategy was the oxidation/
aromatization of the DA adducts to afford xanthone deriva-
tives. The reaction was performed in toluene with DDQ and
the corresponding xanthone derivatives 6a–d were achieved
in good yields (Scheme 2, 57–83%). The synthesized
xanthones possess alkyne substitution in position 4 of the
heterocycle, which, upon reacting with sodium azide in re-
fluxing DMF provided new xanthone-1,2,3-triazole dyads
7a–d in excellent yields (Scheme 2, 88–90%).
In the second strategy an inverse approach was used,
starting with the synthesis of the triazole ring and then the
xanthone skeleton. First, the 1,3-cycloaddition reaction of
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Scheme 3. Strategy for the synthesis of xanthone-1,2,3-triazole dyads 13a–d.
chromones 4a–d with sodium azide afforded the 1,2,3-tri-
azole derivatives 8a–d in excellent yields (Scheme 3, 90–
97%). Subsequently and before the optimization of the DA
reaction we protected the NH of the triazole since it could
undergo a Michael addition reaction with the N-methyl-
maleimide dienophile.[30] N-Protection with the methyl
group was achieved using dimethyl sulfate in refluxing acet-
one and the expected three isomers of 1,2,3-triazoles 9a–
d, 10a–d and 11a–d were prepared in good overall yields
(Scheme 3): 2-NCH3 triazoles 9a–d (higher Rf value) were
isolated as major isomers (67–82%); whereas 3-NCH3 tri-
azoles 10a–d together with 1-NCH3 isomers 11a–d were
obtained as an inseparable mixture in low yields (18–33%).
Analysis of the NMR spectra of this mixture allowed us to
conclude that 1-NCH3 isomers 11a–d were obtained in
trace amounts (see NMR discussion).
At this point and being aware that the DA reaction of
chromone 4a–d only occurs under microwave irradiation
conditions, the reaction of protected 1,2,3-triazole deriva-
tives 9a–d with N-methylmaleimide was optimized using
similar heating conditions. Once more, the lack of reactivity
of the diene resulted in moderate yields of cycloadducts
12a–d (30–40%) and 50–64% of recovered 9a–d when the
reactions were performed in DMF at 160 °C for 20 min,
with microwave irradiation (multimode apparatus). The op-
timization of the reaction using a monomode microwave
apparatus was carried out using 1,2,3-triazole derivative 9c,
in solvent-free conditions, with irradiation times of 5, 10
and 20 min at 200 °C. The best yield of compound 12c was
obtained with a 10 min irradiation; when applying these
conditions to the other derivatives, the yields of cyclo-
adducts 12a–d (36–48%) were slightly better than those ob-
tained using multimode microwave equipment. Further-
more, no side products were detected and 37–51% of start-
ing materials 9a–d were recovered from the reaction mix-
tures. Finally, dehydrogenation of cycloadducts 12a–d lead-
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ing to xanthones 13a–d occurred in the presence of DDQ
oxidant and with good results (Scheme 3, 57–80%).
Nuclear Magnetic Resonance Spectroscopy
The most important features in the 1H NMR spectra of
the (E)-2-(4-arylbut-1-en-3-yn-1-yl)chromones 4a–d are, in
each case: i) two doublets, at δ = 6.66–6.71 and 6.89–
6.93 ppm corresponding to the vinylic protons α-H and β-
H respectively, in a trans configuration (JαH,βH 15–16 Hz),
and ii) a singlet at δ = 6.26–6.28 ppm corresponding to 3-H.
HMBC spectra enabled the assignment of the most relevant
quaternary carbons: C-1 and C-2 at δ = 86.7–88.4 and
96.5–98.4 ppm, respectively, C-2 at δ = 160.0–160.5 ppm, C-
8a and C-4a at δ = 155.9 and 124.1 ppm, respectively, and
C-4 at δ = 178.3 ppm (Figure 1). In the NOESY spectra of
compounds 4a–d NOE cross-peaks were observed between
the 3-H signal and those of α-H and β-H indicating free
rotation around the C2–Cα bond.
The 1H NMR spectra of DA cycloadducts 5a–d, revealed
the disappearance of the structural features mentioned for
4a–d. Furthermore, the 1H NMR spectra showed the pres-
ence of five new signals: i) two multiplets at δ = 3.02–
3.08 ppm and δ = 3.70–3.77 ppm, corresponding to 5-H
and 4-H; ii) a double doublet at δ = 3.28–3.29 ppm, corre-
sponding to 3a-H; iii) a doublet at δ = 4.37–4.39 ppm, cor-
responding to 11b-H; and iv) a singlet at δ = 2.96–
2.98 ppm, corresponding to the 2-NCH3 belonging to N-
methylmaleimide moiety. All these structural features of
compounds 5a–d support the disappearance of structural
features characteristic of compounds 4a–d indicating that
the DA reaction proceeded thereby affording desired cy-
cloadducts 5a–d. Analysis of the 13C NMR spectra enabled
assignment of three carbonyl carbons: C-11 from the chro-
mone moiety, and C-1 and C-3 corresponding to N-methyl-
A. M. S. Silva et al.FULL PAPER
Figure 1. Important connectivities found in the HMBC spectra of the compounds 4a–d, 6a–d, 8a–d and 13a–d.
maleimide. Furthermore, the HMBC spectra of derivatives
5a–d, allowed the assignment of carbons C-1 (δ = 83.3–
84.8 ppm) and C-2 (δ = 85.7–86.0 ppm) through the connec-
tivity with aliphatic protons and with H-2,6, respectively.
The most important characteristics in the 1H NMR spec-
tra of 4-(arylethynyl)-2-methylchromeno[3,2-e]isoindole-
1,3,11(2H)-triones 6a–d are the presence in each case of two
singlets, at δ = 7.85–7.89 ppm corresponding to the aro-
matic protons 5-H, and at δ = 3.26 ppm corresponding to
the protons of the 2-NCH3 group of the N-methylmaleim-
ide moiety. Also, the aliphatic protons characteristic of DA
adducts 5a–d do not appear in the aliphatic regions of the
spectra.
The most relevant structural differences between com-
pounds 6a–d and 7a–d are found in the 13C NMR spectra.
In compounds 6a–d the signals corresponding to C-1 and
C-2, assigned through HMBC analysis, appear at δ = 83.4–
85.0 and 99.0–101.2 ppm, respectively. These signals are not
present in the 13C NMR spectra of compounds 7a–d; in-
stead, analysis of their 13C NMR and HMBC spectra
showed the presence of two signals at δ = 136.3–139.3 ppm
and δ = 142.1–142.7 ppm, corresponding to C-5 and C-4,
respectively, of the 1,2,3-triazole moiety.
The multiplicity of the 1H NMR spectra of the (E)-2-[2-
(4-aryl-2H-1,2,3-triazol-5-yl)vinyl]chromones 8a–d is pretty
much the same as in (E)-2-(4-arylbut-1-en-3-yn-1-yl)chrom-
ones 4a–d. However, the signals of α-H, β-H and 3-H (δ =
7.30–7.35, 7.61–7.68 and 6.58–6.61 ppm, respectively) ap-
pear at higher frequency than those of the same protons in
compounds 4a–d. The deshielding effect of the triazole moi-
ety is more pronounced for α-H and β-H than for the 3-
H protons. As in the case of 4a–d, the NOESY spectra of
compounds 8a–d present NOE cross-peaks between the sig-
nal of 3-H and those of α-H and β-H indicating free rota-
tion around the C2–Cα bond. In the case of the 13C NMR
spectra of compounds 8a–d, the most important feature is
the set of signals for C-4 and C-5, from 1,2,3-triazole moi-
ety, at δ = 137.6–138.3 and 141.8–145.1 ppm, respectively,
assigned from HMBC spectra (Figure 1).
In the 1H NMR spectra of (E)-2-[2-(4-aryl-2-methyl-2H-
1,2,3-triazol-5-yl)vinyl]chromones 9a–d the most relevant
feature is the singlet at δ = 4.28–4.29 ppm corresponding to
2-NCH3 of the methylated 1,2,3-triazole moiety. The un-
equivocal identification of isomers 9a–d and 10a–d was
based on the connectivity found in the HMBC spectra.
Thus, 2-NCH3 protons of isomers 9a–d do not correlate
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with any carbon of the 1,2,3-triazole ring. The position of
the methyl group in the triazole ring of isomers 10a–d was
identified by correlations observed between 2,6-H and
3-NCH3 with C-4 of the 1,2,3-triazole ring. Traces of iso-
mers 11a–d were detected by the presence of less intense
signals of the 1-NCH3 protons and 3-H in the 1H NMR
spectra of the mixture containing both 10a–d and 11a–d
isomers.
Once again, the 1H NMR spectra of the 4-(4-aryl-2-
methyl-2H-1,2,3-triazol-5-yl)-2-methyl-3a,4,5,11b-tetra-
hydrochromeno[3,2-e]isoindole-1,3,11(2H)-triones 12a–d do
not show the structural features described for compounds
8a–d and 9a–d. Indeed, new signals are present in these
spectra: i) two multiplets at δ = 2.96–3.24 and 3.79–
3.91 ppm, corresponding to 5-H and 4-H; ii) a double du-
plet at δ = 3.46–3.48 ppm, due to 3a-H; iii) a doublet at δ
= 4.63–4.64 ppm, assigned to 11b-H; and iv) a singlet at δ
= 2.81–2.82 ppm, attributed to 2-NCH3 of the N-methyl-
maleimide moiety. The key feature in the 1H NMR spectra
of 4-(5-aryl-2-methyl-2H-1,2,3-triazol-4-yl)-2-methyl-
chromeno[3,2-e]isoindole-1,3,11(2H)-triones 13a–d is that
of a singlet at δ = 7.83–7.85 ppm assigned to the 5-H aro-
matic proton in each case. Moreover, the 1H NMR spectra
of compounds 13a–d do not show aliphatic protons indicat-
ing successful aromatization of DA cycloadducts 12a–d.
Conclusions
We have reported the preparation of novel (E)-2-(4-aryl-
but-1-en-3-yn-1-yl)chromone derivatives, which were fur-
ther used as starting materials in two main synthetic routes
to xanthone-1,2,3-triazole dyads. The first strategy involves
the Diels–Alder reaction of the chromone derivatives with
N-methylmaleimide followed by aromatization of the
cycloadducts and reaction with sodium azide to give desired
xanthone-1,2,3-triazole dyads. In the second synthetic ap-
proach an additional step of 1,2,3-triazole protection is re-
quired. Thus, chromone derivatives first react with sodium
azide to provide chromone-1,2,3-triazole dyads, in excellent
yields. After methylation of the triazole NH group, DA re-
action with N-methylmaleimide and subsequent oxidation
with DDQ affords the corresponding cycloadducts.
The DA reactions were performed under both monom-
ode and multimode microwave irradiation conditions. The
former case appears to be a more sustainable and environ-
mentally friendly process since the reaction occurs in sol-
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vent-free conditions, a shorter reaction time and conse-
quently less energy is required. Moreover, yields obtained
in this “greener” fashion were slightly improved relative to
those obtained from the multimode microwave irradiation
conditions.
Experimental Section
General Remarks: Melting points were measured with a Büchi
Melting Point B-540 apparatus. NMR spectra were recorded with
a Bruker Avance 300 spectrometer (300.13 MHz for 1H and
75.47 MHz for 13C) or Bruker Avance 500 spectrometer
(500.13 MHz for 1H and 125.77 MHz for 13C). Chemical shifts (δ)
are reported in ppm and coupling constants (J) in Hz; the internal
standard was TMS. Unequivocal 13C assignments were made with
the aid of 2D gHSQC and gHMBC (delays for one-bond and long-
range J C/H couplings were optimised for 145 and 7 Hz, respec-
tively) experiments. Positive-ion ESI mass spectra were acquired
with a QTOF 2 instrument [dilution of 1 μL of the sample in
chloroform solution (ca. 10–5 m) in 200 μL of 0.1% trifluoroacetic
acid/methanol solution. Nitrogen was used as nebuliser gas and
argon as collision gas. The needle voltage was set at 3000 V, with
the ion source at 80 °C and the desolvation temperature at 150 °C.
The cone voltage was 35 V]. Other low- and high-resolution mass
spectra (EI, 70 eV) were measured with VG Autospec Q and M
spectrometers. Elemental analyses were obtained with a LECO 932
CHNS analyser. Preparative thin-layer chromatography was per-
formed with Merck silica gel (60 DGF254). Column chromatog-
raphy was performed with Merck silica gel (60, 70–230 mesh). All
chemicals and solvents used were obtained from commercial
sources and used as received or dried by standard procedures. 3-
Phenylpropiolaldehyde (3a) was not prepared since it is commer-
cially available (Sigma–Aldrich).
General Procedure for the Synthesis of Arylpropargyl Alcohols 2b–
d: Propargyl alcohol (1.75 mL, 30 mmol) was added to a solution
of the appropriate iodobenzene (20 mmol), bis(triphenylphosphine)
palladium(II) chloride (280 mg, 0.04 mmol), piperidine (3.96 mL,
40 mmol) and copper iodide (114 mg, 0.6 mmol) in toluene
(10 mL), under a nitrogen atmosphere. The mixture was stirred at
60 °C for 2 h and then filtered through Celite 345 and washed with
chloroform. The solvent was evaporated and the residue was puri-
fied by silica gel column chromatography using CH2Cl2 as eluent.
The solvent was evaporated to dryness in each case, and expected
3-arylprop-2-yn-1-ols 2b–d were obtained in good yields (79–95%).
3-(4-Methylphenyl)prop-2-yn-1-ol (2b): Yield 2.31 g (79%). Oil. 1H
NMR (300 MHz, CDCl3): δ = 2.34 (s, 3 H, 4-CH3), 4.48 (d, J =
5.2 Hz, 2 H, 1-H), 7.11 (d, J = 7.9 Hz, 2 H, 3,5-H), 7.33 (d, J =
7.9 Hz, 2 H, 2,6-H) ppm. 13C NMR (75 MHz, CDCl3): δ = 21.4
(4-CH3), 51.6 (C-1), 85.7 (C-3), 86.5 (C-2), 119.3 (C-1), 129.0 (C-
3,5), 131.5 (C-2,6), 138.6 (C-4) ppm. HRMS (ESI+): m/z calcd.
for C10H11O [M + H]+ 147.0810, found 147.0801. MS (ESI+): m/z
(%) = 147 (100) [M + H]+, 315 (35) [2M + Na]+.
3-(4-Methoxyphenyl)prop-2-yn-1-ol (2c): Yield 2.56 g (79%). This
compound showed spectroscopic and analytical data identical to
previously reported data.[31]
3-(4-Bromophenyl)prop-2-yn-1-ol (2d): Yield 4.01 g (95%). This
compound showed spectroscopic and analytical data identical to
previously reported data.[32]
General Procedure for the Synthesis of Arylpropargyl Aldehydes 3b–
d: Activated MnO2 (6.9 g, 79.6 mmol) was added to a solution of
the appropriate arylpropargyl alcohols 2b–d (15.9 mmol) in EtOAc
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(40 mL). The resulting mixture was then refluxed for 1 h. After that
period, the mixture was filtered through Celite 345 and washed
with EtOAc and CH2Cl2. After evaporation of the solvent, the resi-
due was purified by silica gel column chromatography using
CH2Cl2 as eluent. The solvent was evaporated to dryness to give
the expected arylpropynals 3b–d in good yields (86–97%).
3-(4-Methylphenyl)propiolaldehyde (3b): Yield 1.97 g (86%). Oil. 1H
NMR (300 MHz, CDCl3): δ = 2.40 (s, 3 H, 4-CH3), 7.22 (d, J =
8.0 Hz, 2 H, 3,5-H), 7.51 (d, J = 8.0 Hz, 2 H, 2,6-H), 9.41 (s, 1
H, 1-H) ppm. 13C NMR (300 MHz, CDCl3): δ = 21.8 (4-CH3),
88.4 (C-2), 96.0 (C-3), 116.3 (C-1), 129.5 (C-3,5), 133.3 (C-2,6),
142.2 (C-4), 176.9 (C-1) ppm. HRMS (ESI+): m/z calcd. for
C10H9O [M + H]+ 145.0653, found 145.0644. MS (ESI+): m/z (%)
= 189 (55) [M + 2Na]+, 145 (30) [M + H]+.
3-(4-Methoxyphenyl)propiolaldehyde (3c): Yield 2.34 g (92%). This
compound showed spectroscopic and analytical data identical to
previously reported data.[31]
3-(4-Bromophenyl)propiolaldehyde (3d): Yield 3.22 g (97%). This
compound showed spectroscopic and analytical data identical to
previously reported data.[32]
General Procedure for the Synthesis of 2-(4-Arylbut-1-en-3-yn-1-yl)-
4H-chromen-4-ones 4a–d: Sodium (0.11 g, 4.8 mmol) was gradually
added to 5 mL of dry ethanol and the mixture was stirred until the
reaction mixture reached room temperature. 2-Methylchromone 1
(0.2 g, 1.2 mmol) and the appropriate aldehyde 3a–d (1.8 mmol)
were added and the reaction mixture allowed to stand at room
temperature until complete disappearance of chromone 1. After
this period, the solution was poured into ice (20 g) and water
(30 mL) and the pH adjusted to 4 with dilute HCl. The solid was
removed by filtration, taken in CH2Cl2 and purified by silica gel
column chromatography using CH2Cl2 as eluent. The solvent was
evaporated to dryness and the residue were recrystallized from eth-
anol to give the (E)-2-(4-arylbut-1-en-3-yn-1-yl)-4H-chromen-4-
ones 4a–d in good yields (52–80%).
(E)-2-(4-Phenylbut-1-en-3-yn-1-yl)-4H-chromen-4-one (4a): Yield
166 mg (52%), m.p. 127–128 °C (recrystallized from ethanol). 1H
NMR (300 MHz, CDCl3): δ = 6.28 (s, 1 H, 3-H), 6.71 (d, J =
15.7 Hz, 1 H, α-H), 6.93 (d, J = 15.7 Hz, 1 H, β-H), 7.35–7.43 (m,
4 H, 6-H, 3,4,5-H), 7.48 (d, J = 7.7 Hz, 1 H, 8-H), 7.48–7.52
(m, 2 H, 2,6-H), 7.69 (dt, J = 7.7, 1.7 Hz, 1 H, 7-H), 8.19 (dd,
J = 7.9, 1.7 Hz, 1 H, 5-H) ppm. 13C NMR (75 MHz, CDCl3): δ =
87.4 (C-1), 97.8 (C-2), 111.1 (C-3), 117.2 (C-β), 117.9 (C-8), 122.4
(C-1), 124.1 (C-4a), 125.2 (C-6), 125.7 (C-5), 128.5 (C-3,5),
129.2 (C-4), 131.9 (C-2,6), 132.1 (C-α), 134.0 (C-7), 155.9 (C-
8a), 160.2 (C-2), 178.3 (C-4) ppm. C19H12O2: C, 83.81; H, 4.44;
found C, 83.48; H, 4.40. MS (ESI+): m/z (%) = 273 (100) [M +
H]+, 295 (54) [M + Na]+.
(E)-2-[4-(4-Methylphenyl)but-1-en-3-yn-1-yl]-4H-chromen-4-one
(4b): Yield 286 mg (80%), m.p. 148–150 °C (recrystallized from eth-
anol). 1H NMR (300 MHz, CDCl3): δ = 2.38 (s, 3 H, 4-CH3),
6.27 (s, 1 H, 3-H), 6.69 (d, J = 15.8 Hz, 1 H, α-H), 6.93 (d, J =
15.8 Hz, 1 H, β-H), 7.18 (d, J = 8.1 Hz, 2 H, 3,5-H), 7.400 (ddd,
J = 7.6, 7.5, 1.0 Hz, 1 H, 6-H), 7.402 (d, J = 8.1 Hz, 2 H, 2,6-
H), 7.48 (dd, J = 7.9, 1.0 Hz, 1 H, 8-H), 7.69 (ddd, J = 7.9, 7.6,
1.7 Hz, 1 H, 7-H), 8.19 (dd, J = 7.6, 1.7 Hz, 1 H, 5-H) ppm. 13C
NMR (75 MHz, CDCl3): δ = 21.6 (4-CH3), 87.0 (C-1), 98.3 (C-
2), 111.0 (C-3), 117.4 (C-β), 117.9 (C-8), 119.3 (C-1), 124.1 (C-
4a), 125.1 (C-6), 125.7 (C-5), 129.3 (C-3,5), 131.6 (C-α), 131.8
(C-2,6), 133.9 (C-7), 139.6 (C-4), 155.9 (C-8a), 160.4 (C-2),
178.3 (C-4) ppm. C20H14O2: C, 83.90; H, 4.93; found C, 83.51; H,
4.91. MS (ESI+): m/z (%) = 287 (100) [M + H]+, 325 (12) [M +
K]+, 595 (8) [2M + Na]+.
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(E)-2-[4-(4-Methoxyphenyl)but-1-en-3-yn-1-yl]-4H-chromen-4-one
(4c): Yield 302 mg (80%), m.p. 162–163 °C (recrystallized from eth-
anol). 1H NMR (300 MHz, CDCl3): δ = 3.85 (s, 3 H, 4-OCH3),
6.26 (s, 1 H, 3-H), 6.66 (d, J = 15.7 Hz, 1 H, α-H), 6.89 (d, J =
8.6 Hz, 2 H, 3,5-H), 6.93 (d, J = 15.7 Hz, 1 H, β-H), 7.40 (dd,
J = 7.9, 7.8 Hz, 1 H, 6-H), 7.45 (d, J = 8.6 Hz, 2 H, 2,6-H),
7.48 (d, J = 7.6 Hz, 1 H, 8-H), 7.69 (ddd, J = 7.8, 7.6, 1.6 Hz, 1
H, 7-H), 8.19 (dd, J = 7.9, 1.6 Hz, 1 H, 5-H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 55.4 (4-OCH3), 86.7 (C-1), 98.4 (C-2),
110.8 (C-3), 114.2 (C-3,5), 114.4 (C-1), 117.5 (C-β), 117.8 (C-
8), 124.1 (C-4a), 125.1 (C-6), 125.7 (C-5), 131.1 (C-α), 133.5 (C-
2,6), 133.9 (C-7), 155.9 (C-8a), 160.4 (C-4), 160.5 (C-2), 178.3
(C-4) ppm. C20H14O3: C, 79.46; H, 4.67; found C, 79.61; H, 4.83.
MS (ESI+): m/z (%) = 303 (86) [M + H]+, 325 (53) [M + Na]+, 627
(100) [2M + Na]+.
(E)-2-[4-(4-Bromophenyl)but-1-en-3-yn-1-yl]-4H-chromen-4-one
(4d): Yield 259 mg (59%), m.p. 164–166 °C (recrystallized from eth-
anol). 1H NMR (300 MHz, CDCl3): δ = 6.28 (s, 1 H, 3-H), 6.71
(d, J = 15.8 Hz, 1 H, α-H), 6.89 (d, J = 15.8 Hz, 1 H, β-H), 7.36
(d, J = 8.6 Hz, 2 H, 2,6-H), 7.40 (dt, J = 7.8, 0.9 Hz, 1 H, 6-
H), 7.48 (dd, J = 8.7, 0.9 Hz, 1 H, 8-H), 7.51 (d, J = 8.6 Hz, 2 H,
3,5-H), 7.69 (ddd, J = 8.7, 7.8, 1.7 Hz, 1 H, 7-H), 8.19 (dd, J =
7.8, 1.7 Hz, 1 H, 5-H) ppm. 13C NMR (75 MHz, CDCl3): δ = 88.4
(C-1), 96.5 (C-2), 111.3 (C-3), 116.7 (C-β), 117.8 (C-8), 121.3 (C-
1), 123.6 (C-4), 124.1 (C-4a), 125.2 (C-6), 125.7 (C-5), 131.8 (C-
3,5), 132.5 (C-α), 133.2 (C-2,6), 134.0 (C-7), 155.9 (C-8a),
160.0 (C-2), 178.3 (C-4) ppm. C19H11BrO2: C, 64.98; H, 3.16; found
C, 64.71; H, 3.23. MS (ESI+): m/z (%) = 351 (39) [M + H]+ (79Br);
353 (37) [M + H]+ (81Br).
General Procedure for the Synthesis of 4-(Arylethynyl)-2-methyl-
3a,4,5,11b-tetrahydrochromeno[3,2-e]isoindole-1,3,11(2H)-triones
5a–e. Method A: N-Methylmaleimide (0.10 g, 0.92 mmol) was
added to a solution of the appropriate (E)-2-(4-arylbut-1-en-3-yn-
1-yl)-4H-chromen-4-one (4a–d) (0.18 mmol) in dry DMF (5 μL).
The mixture was heated at 160 °C under microwave irradiation
(multimode apparatus) for 20 min. The residue was dissolved in
CH2Cl2 and purified by preparative TLC using CH2Cl2 as eluent
to give desired cycloadducts 5a–d: 5a (19.7 mg, 28%), 5b (19.3 mg,
20%), 5c (22.3 mg, 30%), 5d (25.0 mg, 30%). Adduct 5e was ob-
tained in 14% using the same methodology, under irradiation for
40 min.
Method B: N-Methylmaleimide (0.10 g, 0.92 mmol) was mixed with
the appropriate (E)-2-(4-arylbut-1-en-3-yn-1-yl)-4H-chromen-4-
one 4a–d (0.18 mmol) in a closed vessel. The mixture was heated
at 200 °C under microwave irradiation (monomode apparatus) for
10 min. The residue was dissolved in CH2Cl2 and purified by pre-
parative TLC using CH2Cl2 as eluent to give desired cycloadducts
5a–d: 5a (25.3 mg, 36%), 5b (40.5 mg, 42%), 5c (23.0 mg, 31%), 5d
(37.5 mg, 45%).
2-Methyl-4-(phenylethynyl)-3a,4,5,11b-tetrahydrochromeno[3,2-e]-
isoindole-1,3,11(2H)-trione (5a): M.p. 169–171 °C. 1H NMR
(300 MHz, CDCl3): δ = 2.98 (s, 3 H, CH3), 3.04–3.08 (m, 2 H, 5-
H), 3.29 (dd, J = 7.6, 5.0 Hz, 1 H, 3a-H), 3.73–3.77 (m, 1 H, 4-H),
4 . 3 9 ( d , J = 7 . 6 Hz , 1 H , 1 1b -H ) , 7 . 2 1 – 7 . 2 8 (m , 5 H,
2,3,4,5,6-H), 7.39–7.45 (m, 2 H, 7-H, 9-H), 7.67 (ddd, J =
8.6, 7.1, 1.7 Hz, 1 H, 8-H), 8.29 (dd, J = 8.2, 1.7 Hz, 1 H, 10-
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 24.8 (NCH3), 27.8 (C-
4), 33.2 (C-5), 37.8 (C-11b), 43.2 (C-3a), 84.7 (C-1), 85.8 (C-2),
112.1 (C-11a), 117.6 (C-7), 121.7 (C-1), 123.5 (C-10a), 125.2 (C-
9), 126.4 (C-10), 128.2 (C-2,6), 128.6 (C-4), 131.6 (C-3,5),
133.7 (C-8), 155.7 (C-6a), 162.1 (C-5a), 174.2 (C-3 and C-11), 176.1
(C-1) ppm. HRMS (ESI+): m/z calcd. for C24H18NO4 [M + H]+
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384.1236, found 384.1218. MS (ESI+): m/z (%) = 384 (32) [M +
H]+, 406 (94) [M + Na]+, 789 (100) [2M + Na]+.
2-Methyl-4-[(4-methylphenyl)ethynyl]-3a,4,5,11b-tetrahydro-
chromeno[3,2-e]isoindole-1,3,11(2H)-trione (5b): M.p. 197–199 °C.
1H NMR (300 MHz, CDCl3): δ = 2.28 (s, 3 H, 4-CH3), 2.97 (s, 3
H, N-CH3), 3.03–3.07 (m, 1 H, 5-H), 3.28 (dd, J = 7.6, 5.0 Hz, 1
H, 3a-H), 3.72–3.76 (m, 1 H, 4-H), 4.37 (d, J = 7.6 Hz, 1 H, 11b-
H), 7.01 (d, J = 7.1 Hz, 2 H, 3,5-H), 7.16 (d, J = 7.1 Hz, 2 H,
2,6-H), 7.39–7.44 (m, 2 H, 7-H, 9-H), 7.66 (ddd, J = 8.5, 7.1,
1.7 Hz, 1 H, 8-H), 8.29 (dd, J = 8.2, 1.7 Hz, 1 H, 10-H) ppm. 13C
NMR (75 MHz, CDCl3): δ = 21.4 (4-CH3), 24.8 (N-CH3), 27.8
(C-4), 33.2 (C-5), 37.7 (C-11b), 43.3 (C-3a), 84.0 (C-1), 85.9 (C-
2), 112.1 (C-11a), 117.6 (C-9), 118.6 (C-1), 123.5 (C-10a), 125.2
(C-7), 126.4 (C-10), 129.0 (C-3,5), 131.4 (C-2,6), 133.7 (C-8),
138.8 (C-4), 155.7 (C-6a), 162.2 (C-5a), 174.3 (C-3), 176.2 (C-1
and C-11) ppm. HRMS (ESI+): m/z calcd. for C25H20NO4 [M +
H]+ 398.1392, found 398.1372. MS (ESI+): m/z (%) = 398 (100) [M
+ H]+, 420 (21) [M + Na]+, 817 (27) [2M + Na]+.
4-[(4-Methoxyphenyl)ethynyl]-2-methyl-3a,4,5,11b-tetrahydro-
chromeno[3,2-e]isoindole-1,3,11(2H)-trione (5c): M.p. 203–204 °C.
1H NMR (300 MHz, CDCl3): δ = 2.97 (s, 3 H, NCH3), 3.02–3.07
(m, 2 H, 5-H), 3.28 (dd, J = 7.6, 5.0 Hz, 1 H, 3a-H), 3.71–3.75 (m,
1 H, 4-H), 3.75 (s, 3 H, OCH3), 4.37 (d, J = 7.6 Hz, 1 H, 11b-H),
6.73 (d, J = 8.9 Hz, 2 H, 3,5-H), 7.20 (d, J = 8.9 Hz, 2 H, 2,6-
H), 7.39–7.44 (m, 2 H, 7-H, 9-H), 7.66 (ddd, J = 8.6, 7.1, 1.7 Hz,
1 H, 8-H), 8.29 (dd, J = 8.2, 1.7 Hz, 1 H, 10-H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 24.7 (NCH3), 27.8 (C-4), 33.3 (C-5), 37.7
(C-11b), 43.3 (C-3a), 55.2 (OCH3), 83.3 (C-1), 85.7 (C-2), 112.1
(C-11a), 113.7 (C-1), 113.8 (C-3,5), 117.6 (C-7), 123.5 (C-10a),
125.2 (C-9), 126.4 (C-10), 133.0 (C-2,6), 133.7 (C-8), 155.7 (C-
6a), 159.7 (C-4), 162.3 (C-5a), 174.3 (C-1), 176.2 (C-3 and C-
11) ppm. HRMS (ESI+): m/z calcd. for C25H20NO5 [M + H]+
414.1341, found 414.1329. MS (ESI+): m/z (%) = 414 (22) [M +
H]+, 436 (38) [M + Na]+, 849 (100) [2M + Na]+.
4-[(4-Bromophenyl)ethynyl]-2-methyl-3a,4,5,11b-tetrahydro-
chromeno[3,2-e]isoindole-1,3,11(2H)-trione (5d): M.p. 214–215 °C.
1H NMR (300 MHz, CDCl3): δ = 2.96 (s, 3 H, CH3), 3.03–3.08 (m,
2 H, 5-H), 3.29 (dd, J = 7.6, 5.0 Hz, 1 H, 3a-H), 3.70–3.75 (m, 1
H, 4-H), 4.39 (d, J = 7.6 Hz, 1 H, 11b-H), 7.14 (d, J = 8.5 Hz, 2
H, 2-H, 6-H), 7.36 (d, J = 8.5 Hz, 2 H, 3-H, 5-H), 7.40–7.45
(m, 2 H, 7-H, 9-H), 7.67 (ddd, J = 8.5, 7.1, 1.6 Hz, 1 H, 8-H), 8.29
(dd, J = 8.2, 1.6 Hz, 1 H, 10-H) ppm. 13C NMR (75 MHz, CDCl3):
δ = 24.8 (NCH3), 27.8 (C-4), 33.0 (C-5), 37.8 (C-11b), 43.2 (C-3a),
84.8 (C-1), 86.0 (C-2), 112.1 (C-11a), 117.6 (C-7), 120.6 (C-1),
123.0 (C-4), 123.8 (C-10a), 125.3 (C-9), 126.4 (C-10), 131.5 (C-
3 and C-5), 133.0 (C-2 and C-6), 133.8 (C-8), 155.7 (C-6a),
162.3 (C-5a), 175.9 (C-1), 176.0 (C-3 and C-11) ppm. HRMS
(ESI+): m/z calcd. for C24H1779BrNO4 [M + H]+ 462.0341, found
462.0325; calcd. for C24H1781BrNO4 [M + H]+ 464.0320, found
464.0302. MS (ESI+): m/z (%) = 462 (35) [M + H]+, 947 (100) [2M
+ Na + 2H]+.
4-[(4-Methoxyphenyl)ethynyl]-2-phenyl-3a,4,5,11b-tetrahydro-
chromeno[3,2-e]isoindole-1,3,11(2H)-trione (5e): M.p. 164–166 °C.
1H NMR (300 MHz, CDCl3): δ = 3.10–3.13 (m, 2 H, 5-H), 3.37
(dd, J = 7.7, 4.9 Hz, 1 H, 3-H), 3.71 (s, 3 H, 4-OCH3), 3.87–3.90
(m, 1 H, 4-H), 4.56 (d, J = 4.9 Hz, 1 H, 11b-H), 6.64 (d, J = 6.9 Hz,
2 H, 3,5-H), 7.08 (d, J = 6.9 Hz, 2 H, 2,6-H), 7.27–7.34 (m,
5 H, 2,3,4,5,6-H), 7.39–7.43 (m, 1 H, 9-H), 7.43 (d, J
= 7.7 Hz, 1 H, 7-H), 7.66 (ddd, J = 7.8, 7.7, 1.6 Hz, 1 H, 8-H),
8.28 (dd, J = 8.3, 1.6 Hz, 1 H, 10-H) ppm. 13C NMR (75 MHz,
CDCl3): δ = 27.9 (C-4), 33.8 (C-5), 38.1 (C-11b), 43.0 (C-3a), 55.2
(OCH3), 83.5 (C-1), 86.5 (C-2), 112.0 (C-11a), 113.66 (C-1),
(E)-2-(4-Arylbut-1-en-3-yn-1-yl)chromones as Synthons
113.73 (C-3,5), 117.7 (C-7), 123.6 (C-10a), 125.3 (C-9), 126.4
(C-10), 126.6 (C-2,6), 128.4 (C-4), 128.9 (C-3,5), 131.8
(C-1), 133.3 (C-2,6), 133.7 (C-8), 155.8 (C-6a), 159.7 (C-4),
162.4 (C-5a), 173.0 (C-3), 175.3 (C-1), 176.2 (C-11) ppm.
General Procedure for the Synthesis of 4-(Arylethynyl)-2-methyl-
chromeno[3,2-e]isoindole-1,3,11(2H)-triones 6a–d: 2,3-Dichloro-5,6-
dicyanobenzoquinone (DDQ) (121 mg, 534 μmol) was added to a
solution of the appropriate 4-(arylethynyl)-2-methyl-3a,4,5,11b-
tetrahydrochromeno[3,2-e]isoindole-1,3,11(2H)-triones 5a–d
(178 μmol) in toluene (10 mL). The mixture was stirred at 100 °C
for 1 h. After that period, the solvent was evaporated to dryness
and the residue was purified by preparative TLC using CH2Cl2
as eluent to give desired 4-(arylethynyl)-2-methylchromeno[3,2-e]
isoindole-1,3,11-triones 6a–d in good yields (57–83%).
2-Methyl-4-(phenylethynyl)chromeno[3,2-e]isoindole-1,3,11(2H)-
trione (6a): Yield 42.5 mg (63%), m.p. 273–274 °C. 1H NMR
(300 MHz, CDCl3): δ = 3.26 (s, 3 H, CH3), 7.42–7.47 (m, 4 H, 9-
H, 3,4,5-H), 7.50 (dd, J = 8.3, 0.6 Hz, 1 H, 7-H), 7.71–7.73
(m, 2 H, 2,6-H), 7.77 (ddd, J = 8.3, 7.1, 1.6 Hz, 1 H, 8-H), 7.89
(s, 1 H, 5-H), 8.36 (dd, J = 8.0, 1.6 Hz, 1 H, 10-H) ppm. 13C NMR
(75 MHz, CDCl3): δ = 24.5 (NCH3), 84.0 (C-1), 100.4 (C-2), 117.6
(C-7), 118.9 (C-11a), 121.8 (C-11b), 123.0 (C-10a), 124.8 (C-4),
125.1 (C-9), 127.0 (C-5), 127.4 (C-10), 128.6 (C-3,5), 128.8 (C-
3a), 129.9 (C-4), 132.4 (C-2,6), 133.6 (C-1), 135.5 (C-8), 155.0
(C-6a), 159.6 (C-5a), 164.1 and 165.9 (C-1 and C-3), 174.0 (C-
11) ppm. HRMS (ESI): m/z calcd. for C24H14NO4 [M + H]+
380.0923, found 380.0907. MS (ESI+): m/z (%) = 380 (40) [M + H]
+, 402 (21) [M + Na]+, 781 (100) [2M + Na]+, 797 (27) [2M +
K]+.
2-Methyl-4-[(4-methylphenyl)ethynyl]chromeno[3,2-e]isoindole-
1,3,11(2H)-trione (6b): Yield 53.9 mg (77%), m.p. 326–327 °C. 1H
NMR (300 MHz, CDCl3): δ = 2.41 (s, 3 H, CH3), 3.26 (s, 3 H, N-
CH3), 7.24 (d, J = 8.0 Hz, 2 H, 3,5-H), 7.45 (t, J = 7.8 Hz, 1 H,
9-H), 7.50 (d, J = 8.3 Hz, 1 H, 7-H), 7.62 (d, J = 8.0 Hz, 2 H,
2,6-H), 7.77 (ddd, J = 8.3, 7.8, 1.5 Hz, 1 H, 8-H), 7.88 (s, 1 H,
5-H), 8.37 (dd, J = 7.8, 1.5 Hz, 1 H, 10-H) ppm. 13C NMR
(500 MHz, CDCl3): δ = 21.8 (CH3), 24.5 (NCH3), 83.7 (C-1),
100.9 (C-2), 117.6 (C-7), 118.7 (C-1), 118.8 (C-3a), 123.0 (C-10a),
125.07 (C-11b), 125.12 (C-9), 126.8 (C-5), 127.4 (C-10), 128.7 (C-
11a), 129.4 (C-3,5), 132.3 (C-2,6), 133.6 (C-4), 135.4 (C-8),
140.5 (C-4), 155.0 (C-6a), 159.7 (C-5a), 164.1 and 166.0 (C-1 and
C-3), 174.1 (C-11) ppm. HRMS (ESI+): m/z calcd. for C25H16NO4
[M + H]+ 394.1079, found 394.1060. MS (ESI+): m/z (%) = 394
(40) [M + H]+, 416 (72) [M + Na]+, 432 (33) [M + K]+, 809 (100)
[2M + Na]+, 825 (43) [2M + K]+.
4-[(4-Methoxyphenyl)ethynyl]-2-methylchromeno[3,2-e]isoindole-
1,3,11(2H)-trione (6c): Yield 60.5 mg (83%), m.p. 295–297 °C. 1H
NMR (500 MHz, CDCl3): δ = 3.26 (s, 3 H, NCH3), 3.87 (s, 3 H,
OCH3), 6.95 (d, J = 8.9 Hz, 2 H, 3,5-H), 7.44 (ddd, J = 7.8, 7.3,
1.0 Hz, 1 H, 9-H), 7.50 (dd, J = 8.4, 1.0 Hz, 1 H, 7-H), 7.68 (d, J
= 8.9 Hz, 2 H, 2,6-H), 7.77 (ddd, J = 8.4, 7.3, 1.6 Hz, 1 H, 8-
H), 7.85 (s, 1 H, 5-H), 8.37 (dd, J = 7.8, 1.6 Hz, 1 H, 10-H) ppm.
13C NMR (126 MHz, CDCl3): δ = 24.5 (NCH3), 55.4 (OCH3), 83.4
(C-1), 101.2 (C-2), 113.8 (C-1), 114.3 (C-3,5), 117.6 (C-7),
118.6 (C-11a), 123.0 (C-10a), 125.1 (C-9), 125.3 (C-11b), 126.5 (C-
5), 127.4 (C-10), 128.5 (C-3a), 133.6 (C-4), 134.2 (C-2,6), 135.4
(C-8), 155.0 (C-6a), 159.7 (C-5a), 161.0 (C-4), 164.2 and 166.1
(C-1 and C-3), 174.1 (C-11) ppm. HRMS (ESI+): m/z calcd. for
C25H16NO5 [M + H]+ 410.1028, found 410.1007. MS (ESI+): m/z
(%) = 410 (14) [M + H]+, 432 (30) [M + Na]+, 448 (15) [M + K]+,
841 (100) [2M + Na]+, 857 (47) [2M + K]+.
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4-[(4-Bromophenyl)ethynyl]-2-methylchromeno[3,2-e]isoindole-
1,3,11(2H)-trione (6d): Yield 46.5 mg (57%), m.p. 332–333 °C. 1H
NMR (500 MHz, CDCl3): δ = 3.26 (s, 3 H, NCH3), 7.45 (ddd, J =
8.0, 7.1, 0.9 Hz, 1 H, 9-H), 7.51 (d, J = 8.2 Hz, 1 H, 7-H), 7.56–
7.60 (m, 4 H, 2,6-H, 3,5-H), 7.78 (ddd, J = 8.2, 7.1, 1.6 Hz,
1 H, 8-H), 7.88 (s, 1 H, 5-H), 8.37 (dd, J = 8.0, 1.6 Hz, 1 H, 10-
H) ppm. 13C NMR (126 MHz, CDCl3): δ = 24.5 (NCH3), 85.0 (C-
1), 99.0 (C-2), 117.6 (C-7), 119.1 (C-11a), 120.7 (C-1), 123.0 (C-
10a), 124.3 and 124.5 (C-4 and C-11b), 125.2 (C-9), 126.9 (C-5),
127.5 (C-10), 128.8 (C-3a), 132.0 (C-3,5), 133.5 (C-4), 133.7
(C-2,6), 135.5 (C-8), 155.0 (C-6a), 159.7 (C-5a), 164.1 and 166.2
(C-1 and C-3), 174.0 (C-11) ppm. HRMS (ESI+): m/z calcd. for
C24H1379BrNO4 [M + H]+ 458.0028, found 458.0006; calcd. for
C24H1381BrNO4 [M + H]+ 460.0007, found 459.9986. MS (ESI+):
m/z (%) = 480 (23) [M + Na]+, 497 (12) [M + K]+, 939 (19) [2M +
Na]+.
General Procedure for the Synthesis of 4-(4-Aryl-2H-1,2,3-triazol-5-
yl)-2-methylchromeno[3,2-e]isoindole-1,3,11(2H)-triones 7a–d: So-
dium azide (43 mg, 660 μmol) was added to a solution of the appro-
priate 4-(arylethynyl)-2-methylchromeno[3,2-e] isoindole-
1,3,11(2H)-trione 6a–d (132 μmol) in dry DMF (5 mL). The mix-
ture was stirred under reflux for 1 h under nitrogen atmosphere.
After that period, the solution was poured into ice (30 g) and water
(30 mL), and the pH was adjusted to 4 with diluted HCl. The mix-
ture was vigorously stirred for 15 min, the precipitate was removed
by filtration, washed with water (3 20 mL) and light petroleum
(3 20 mL), and recrystallized from ethanol to afford desired
xanthone-1,2,3-triazole dyads 7a–d in excellent yields (88–90%).
2-Methyl-4-(4-phenyl-2H-1,2,3-triazol-5-yl)chromeno[3,2-e]iso-
indole-1,3,11(2H)-trione (7a): Yield 49.6 mg (89%), m.p. 304–
306 °C. 1H NMR [500 MHz, (CD3)2SO + TFA]: δ = 2.94 (s, 3 H,
NCH3), 7.30–7.34 (m, 3 H, 3,4,5-H), 7.47 (dd, J = 7.8, 1.7 Hz,
2 H, 2,6-H), 7.55 (ddd, J = 7.7, 7.3, 0.9 Hz, 1 H, 9-H), 7.68 (d,
J = 8.4 Hz, 1 H, 7-H), 7.91 (ddd, J = 8.4, 7.3, 1.5 Hz, 1 H, 8-H),
8.04 (s, 1 H, 5-H), 8.24 (dd, J = 7.7, 1.5 Hz, 1 H, 10-H) ppm. 13C
NMR [126 MHz, (CD3)2SO + TFA]: δ = 24.2 (NCH3), 118.0 (C-
7), 119.4 (C-11a), 122.7 (C-10a), 125.3 (C-9), 126.4 (C-5), 126.5 (C-
10), 126.9 (C-2,6), 127.5 (C-3a), 128.4 (C-4), 128.9 (C-3,5),
129.9 (C-1), 133.7 and 133.8 (C-4 and C-11b), 136.0 (C-8), 136.8
(C-5), 142.7 (C-4), 154.8 (C-6a), 159.5 (C-5a), 163.9 and 165.4
(C-1 and C-3), 173.6 (C-11) ppm. HRMS (ESI+): m/z calcd. for
C24H15N4O4 [M + H]+ 423.1093, found 423.1076. MS (ESI+): m/z
(%) = 423 (100) [M + H]+, 445 (10) [M + Na]+.
2-Methyl-4-[4-(4-methylphenyl)-2H-1,2,3-triazol-5-yl]chromeno-
[3,2-e]isoindole-1,3,11(2H)-trione (7b): Yield 51.8 mg (90%), m.p.
318–320 °C. 1H NMR [500 MHz, (CD3)2SO + TFA]: δ = 2.23 (s, 3
H, CH3), 2.92 (s, 3 H, NCH3), 7.09 (d, J = 8.1 Hz, 2 H, 3,5-H),
7.32 (d, J = 8.1 Hz, 2 H, 2,6-H), 7.49 (t, J = 7.6 Hz, 1 H, 9-H),
7.61 (d, J = 8.0 Hz, 1 H, 7-H), 7.86 (ddd, J = 8.0, 7.6, 1.6 Hz, 1
H, 8-H), 7.96 (s, 1 H, 5-H), 8.21 (dd, J = 7.6, 1.6 Hz, 1 H, 10-
H) ppm. 13C NMR [126 MHz, (CD3)2SO + TFA]: δ = 20.9 (CH3),
24.3 (NCH3), 118.2 (C-7), 119.7 (C-11a), 123.0 (C-10a), 125.5 (C-
9), 126.6 (C-5), 126.8 (C-10), 127.1 (C-2,6), 127.2 (C-1), 127.8
(C-3a), 129.7 (C-3,5), 134.0 and 134.2 (C-4 and C-11b), 136.1
(C-8), 136.8 (C-5), 138.2 (C-4), 142.6 (C-4), 155.1 (C-6a), 159.8
(C-5a), 164.2 and 165.7 (C-1 and C-3), 173.9 (C-11) ppm. HRMS
(ESI+): m/z calcd. for C25H17N4O4 [M + H]+ 437.1250, found
437.1228. MS (ESI+): m/z (%) = 437 (100) [M + H]+, 459 (71) [M
+ Na]+, 475 (38) [M + K]+, 895 (78) [2M + Na]+.
4-[4-(4-Methoxyphenyl)-2H-1,2,3-triazol-5-yl]-2-methylchromeno-
[3,2-e]isoindole-1,3,11(2H)-trione (7c): Yield 52.5 mg (88%), m.p.
297–299 °C. 1H NMR [500 MHz, (CD3)2SO + TFA]: δ = 2.93 (s, 3
A. M. S. Silva et al.FULL PAPER
H, NCH3), 3.69 (s, 3 H, OCH3), 6.84 (d, J = 8.9 Hz, 2 H, 3,5-
H), 7.36 (d, J = 8.9 Hz, 2 H, 2,6-H), 7.50 (ddd, J = 7.8, 7.3,
0.8 Hz, 1 H, 9-H), 7.63 (d, J = 8.3 Hz, 1 H, 7-H), 7.87 (ddd, J =
8.3, 7.3, 1.5 Hz, 1 H, 8-H), 7.97 (s, 1 H, 5-H), 8.22 (dd, J = 7.8,
1.5 Hz, 1 H, 10-H) ppm. 13C NMR [126 MHz, (CD3)2SO + TFA]:
δ = 24.2 (NCH3), 55.2 (OCH3), 114.5 (C-3,5), 118.1 (C-7), 119.5
(C-11a), 122.2 (C-1), 122.9 (C-10a), 125.4 (C-9), 126.5 (C-5),
126.6 (C-10), 127.7 (C-3a), 128.4 (C-2,6), 133.8 and 134.2 (C-4
and C-11b), 136.1 (C-8), 136.3 (C-5), 142.1 (C-4), 154.9 (C-6a),
159.6 and 159.7 (C-4 and C-5a), 164.1 and 165.6 (C-1 and C-3),
173.8 (C-11) ppm. HRMS (ESI+): m/z calcd. for C25H17N4O5 [M
+ H]+ 453.1199, found 453.1177. MS (ESI+): m/z (%) = 437 (16)
[M – CH3]+, 453 (100) [M + H]+, 475 (77) [M + Na]+, 491 (33) [M
+ K]+, 927 (64) [2M + Na]+.
4-[4-(4-Bromophenyl)-2H-1,2,3-triazol-5-yl]-2-methylchromeno-
[3,2-e]isoindole-1,3,11(2H)-trione (7d): Yield 59.5 mg (90%), m.p.
319–320 °C. 1H NMR [500 MHz, (CD3)2SO + TFA]: δ = 2.92 (s, 3
H, NCH3), 7.39 (d, J = 8.7 Hz, 2 H, 2,6-H), 7.47 (d, J = 8.7 Hz,
2 H, 3,5-H), 7.51 (ddd, J = 7.8, 7.3, 0.9 Hz, 1 H, 9-H), 7.64 (dd,
J = 8.2, 0.9 Hz, 1 H, 7-H), 7.88 (ddd, J = 8.2, 7.3, 1.6 Hz, 1 H, 8-
H), 8.02 (s, 1 H, 5-H), 8.22 (dd, J = 7.8, 1.6 Hz, 1 H, 10-H) ppm.
13C NMR [126 MHz, (CD3)2SO + TFA]: δ = 24.3 (NCH3), 118.2
(C-7), 119.7 (C-11a), 121.9 (C-4), 122.9 (C-10a), 125.5 (C-9),
126.6 (C-5), 126.7 (C-10), 127.6 (C-3a), 129.0 (C-2,6), 129.7 (C-
1), 132.1 (C-3,5), 133.5 and 134.0 (C-4 and C-11b), 136.2 (C-
8), 139.3 (C-5), 142.5 (C-4), 155.0 (C-6a), 159.8 (C-5a), 164.1 and
165.7 (C-1 and C-3), 173.8 (C-11) ppm. HRMS (ESI+): m/z calcd.
for C24H1479BrN4O4 [M + H]+ 501.0198, found 501.0180; calcd. for
C24H1481BrN4O4 [M + H]+ 503.0178, found 503.0155. MS (ESI+):
m/z (%) = 501 (100) [M + H]+.
General Procedure for the Synthesis of (E)-2-[2-(4-Aryl-2H-1,2,3-
triazol-5-yl)vinyl]-4H-chromen-4-ones (8a–d): Sodium azide
(117 mg, 1.8 mmol) was added to a solution of the appropriate (E)-
2-(4-arylbut-1-en-3-yn-1-yl)-4H-chromen-4-ones 4a–d (367 μmol)
in dry DMF (5 mL). The mixture was stirred under reflux for 1 h
under nitrogen atmosphere. After that period, the solution was
poured into ice (30 g) and water (30 mL), and the pH was adjusted
to 4 with diluted HCl. The mixture was vigorously stirred for
15 min, the precipitate was washed with water (3 20 mL) and
light petroleum (3 20 mL), removed by filtration and recrys-
tallized from ethanol to give (E)-2-[2-(4-aryl-2H-1,2,3-triazol-5-yl)
vinyl]-4H-chromen-4-ones 8a–d in excellent yields (90–97%).
(E)-2-[2-(4-Phenyl-2H-1,2,3-triazol-5-yl)vinyl]-4H-chromen-4-one
(8a): Yield 0.10 g (90%), m.p. 240–241 °C. 1H NMR [300 MHz,
(CD3)2SO + TFA]: δ = 6.58 (s, 1 H, 3-H), 7.35 (d, J = 15.8 Hz, 1
H, α-H), 7.46 (t, J = 7.7 Hz, 1 H, 6-H), 7.53 (t, J = 7.5 Hz, 1 H,
4-H), 7.61 (t, J = 7.5 Hz, 2 H, 3,5-H), 7.65 (d, J = 8.1 Hz, 1
H, 8-H), 7.68 (d, J = 15.8 Hz, 1 H, β-H), 7.74 (d, J = 7.5 Hz, 2 H,
2,6-H), 7.77 (ddd, J = 8.1, 7.7, 1.5 Hz, 1 H, 7-H), 8.06 (dd, J =
7.7, 1.5 Hz, 1 H, 5-H) ppm. 13C NMR [126 MHz, (CD3)2SO +
TFA]: δ = 111.1 (C-3), 118.7 (C-8), 123.1 (C-α), 123.9 (C-4a), 124.0
(C-β), 125.3 (C-5), 125.6 (C-6), 128.5 (C-2,6), 129.3 (C-1),
129.4 (C-4), 129.6 (C-3,5), 134.5 (C-7), 138.3 (C-4), 142.6 (C-
5), 156.0 (C-8a), 161.5 (C-2), 177.7 (C-4) ppm. HRMS (ESI+): m/z
calcd. for C19H14N3O2 [M + H]+ 316.1086, found 316.1075. MS
(ESI+): m/z (%) = (100) 316 [M + H]+, 653 (22) [2M + Na]+.
(E)-2-{2-[4-(4-Methylphenyl)-2H-1,2,3-triazol-5-yl]vinyl}-4H-
chromen-4-one (8b): Yield 0.12 g (98%), m.p. 239–240 °C. 1H NMR
[300 MHz, (CD3)2SO + TFA]: δ = 2.42 (s, 3 H, CH3), 6.61 (s, 1 H,
3-H), 7.34 (d, J = 15.8 Hz, 1 H, α-H), 7.41 (d, J = 7.7 Hz, 2 H,
3,5-H), 7.48 (t, J = 7.7 Hz, 1 H, 6-H), 7.61 (d, J = 7.7 Hz, 2 H,
2,6-H), 7.64 (d, J = 15.8 Hz, 1 H, β-H), 7.70 (d, J = 8.0 Hz, 1
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H, 8-H), 7.80 (ddd, J = 8.0, 7.7, 1.4 Hz, 1 H, 7-H), 8.03 (dd, J =
7.7, 1.4 Hz, 1 H, 5-H) ppm. 13C NMR [126 MHz, (CD3)2SO +
TFA]: δ = 21.0 (CH3), 110.7 (C-3), 118.5 (C-8), 122.4 (C-α), 123.6
(C-β), 123.8 (C-4a), 124.9 (C-5), 125.4 (C-6), 125.7 (C-1), 128.1
(C-2 and C-6), 129.9 (C-3 and C-5), 134.3 (C-7), 137.8 (C-
4), 138.8 (C-4), 141.8 (C-5), 155.5 (C-8a), 161.1 (C-2), 177.3 (C-
4) ppm. HRMS-EI: m/z calcd. for C20H15O2N3 M+· 329.1164,
found 329.1166. MS (ESI+): m/z (%) = 330 (100) [M + H]+, 352
(15) [M + Na]+.
(E)-2-{2-[4-(4-Methoxyphenyl)-2H-1,2,3-triazol-5-yl]vinyl}-4H-
chromen-4-one (8c): Yield 0.12 g (98%), m.p. 237–238 °C. 1H NMR
[500 MHz, (CD3)2SO + TFA]: δ = 3.85 (s, 3 H, OCH3), 6.60 (s, 1
H, 3-H), 7.16 (d, J = 8.8 Hz, 2 H, 3,5-H), 7.32 (d, J = 15.8 Hz,
1 H, α-H), 7.46 (ddd, J = 7.7, 7.2, 1.0 Hz, 1 H, 6-H), 7.62 (d, J =
15.8 Hz, 1 H, β-H), 7.64 (d, J = 8.8 Hz, 2 H, 2,6-H), 7.70 (d, J
= 8.1 Hz, 1 H, 8-H), 7.79 (ddd, J = 8.1, 7.2, 1.6 Hz, 1 H, 7-H),
8.01 (dd, J = 7.7, 1.6 Hz, 1 H, 5-H) ppm. 13C NMR [126 MHz,
(CD3)2SO + TFA]: δ = 55.4 (OCH3), 110.6 (C-3), 114.8 (C-3,5),
118.5 (C-8), 120.7 (C-1), 122.2 (C-α), 123.6 (C-4a), 123.9 (C-β),
124.9 (C-5), 125.4 (C-6), 129.6 (C-2,6), 134.3 (C-7), 137.6 (C-
4), 145.1 (C-5), 155.5 (C-8a), 160.1 (C-4), 161.2 (C-2), 177.2 (C-
4) ppm. HRMS-EI: m/z calcd. for C20H15O3N3 M+· 345.1113,
found 345.1116. MS (ESI+): m/z (%) = 346 (100) [M + H]+, 368
(15) [M + Na]+.
(E)-2-{2-[4-(4-Bromophenyl)-2H-1,2,3-triazol-5-yl]vinyl}-4H-
chromen-4-one (8d): Yield 0.14 g (97%), m.p. 293–294 °C. 1H NMR
[300 MHz, (CD3)2SO + TFA]: δ = 6.58 (s, 1 H, 3-H), 7.30 (d, J =
15.8 Hz, 1 H, α-H), 7.42 (ddd, J = 7.7, 7.4, 1.3 Hz, 1 H, 6-H), 7.61
(d, J = 15.8 Hz, 1 H, β-H), 7.64 (d, J = 8.5 Hz, 2 H, 2,6-H),
7.68 (d, J = 7.8 Hz, 1 H, 8-H), 7.73–7.78 (m, 1 H, 7-H), 7.75 (d, J
= 8.5 Hz, 2 H, 3,5-H), 8.00 (dd, J = 7.7, 1.3 Hz, 1 H, 5-H) ppm.
13C NMR [75 MHz, (CD3)2SO + TFA]: δ = 111.1 (C-3), 118.8 (C-
8), 122.8 (C-4), 123.5 (C-α, C-β), 123.9 (C-4a), 125.1 (C-5), 125.6
(C-6), 128.7 (C-1), 130.3 (C-2,6), 132.5 (C-3,5), 134.5 (C-
7), 138.2 (C-4), 142.2 (C-5), 155.8 (C-8a), 161.2 (C-2), 177.6 (C-
4) ppm. HRMS-EI: m/z calcd. for C19H12O2N379Br M+· 393.0113,
found 393.0122; calcd. for C19H12O2N381Br M+· 395.0092, found
395.0106. MS (ESI+): m/z (%) = 394 (39) [M + H]+ (79Br); (37) 396
[M + H]+ (81Br).
General Procedure for the Synthesis of (E)-2-[2-(4-Aryl-2-methyl-
2H-1,2,3-triazol-5-yl)vinyl]-4H-chromen-4-ones 9a–d, (E)-2-[2-(4-
Aryl-3-methyl-2H-1,2,3-triazol-5-yl)vinyl]-4H-chromen-4-ones 10a–
d and (E)-2-[2-(4-Aryl-1-methyl-2H-1,2,3-triazol-5-yl)vinyl]-4H-
chromen-4-ones 11a–d: Dimethyl sulfate (0.1 mL, 1.1 mmol) was
added dropwise to a solution of the appropriate (E)-2-[2-(4-aryl-
2H-1,2,3-triazol-5-yl)vinyl]-4H-chromen-4-one 8a–d (1 mmol) in
acetone (10 mL) with potassium carbonate (0.36 g, 3 mmol). The
mixture was stirred under reflux for 1 h. The inorganic salts were
removed by filtration and washed with acetone (3 30 mL). The
solvent was evaporated to dryness and the residue was purified by
silica column chromatography using CH2Cl2 as eluent. Two frac-
tions were obtained: 1,2,3-triazole derivatives 9a–d (higher Rf
value) in 67–82% yield and a mixture of 10a–d and 11a–d in 18–
33% yield.
(E)-2-[2-(2-Methyl-4-phenyl-2H-1,2,3-triazol-5-yl)vinyl]-4H-
chromen-4-one (9a): Yield 221 mg (67%), m.p. 169–171 °C. 1H
NMR (300 MHz, CDCl3): δ = 4.29 (s, 3 H, NCH3), 6.34 (s, 1 H,
3-H), 7.12 (d, J = 15.8 Hz, 1 H, α-H), 7.39 (ddd, J = 8.0, 7.1,
0.8 Hz, 1 H, 6-H), 7.47 (dd, J = 8.2, 0.8 Hz, 1 H, 8-H), 7.48–7.57
(m, 3 H, 3,4,5-H), 7.61 (d, J = 15.8 Hz, 1 H, β-H), 7.64–7.70
(m, 3 H, 7-H, 2,6-H), 8.19 (dd, J = 8.0, 1.5 Hz, 1 H, 5-H) ppm.
13C NMR (75 MHz, CDCl3): δ = 42.2 (NCH3), 111.3 (C-3), 117.9
(E)-2-(4-Arylbut-1-en-3-yn-1-yl)chromones as Synthons
(C-8), 123.2 (C-α), 124.0 (C-β), 124.1 (C-4a), 125.1 (C-6), 125.7 (C-
5), 128.3 (C-2,6), 128.9 (C-4), 129.0 (C-3,5), 130.1 (C-1),
133.8 (C-8), 140.5 (C-5), 147.4 (C-4), 155.9 (C-8a), 161.1 (C-2),
178.5 (C-4) ppm. HRMS (ESI+): m/z calcd. for C20H16N3O2 [M +
H]+ 330.1243, found 330.1231. MS (ESI+): m/z (%) = 330 (100)
[2M + H]+, 659 (7) [2M + H]+.
Mixture of 10a and 11a (86:14): Yield 109 mg (33%). (E)-2-[2-(3-
Methyl-4-phenyl-1H-1,2,3-triazol-5-yl)vinyl]-4H-chromen-4-one
(10a): 1H NMR (500 MHz, CDCl3): δ = 4.02 (s, 3 H, NCH3), 6.30
(s, 1 H, 3-H), 7.21 (d, J = 15.8 Hz, 1 H, α-H), 7.36 (d, J = 15.8 Hz,
1 H, β-H), 7.38 (ddd, J = 7.7, 7.5, 1.0 Hz, 1 H, 6-H), 7.41–7.43 (m,
3 H, 8-H, 2,6-H), 7.61–7.65 (m, 4 H, 7-H, 3,4,5-H), 8.17
(dd, J = 7.5, 1.5 Hz, 1 H, 5-H) ppm. 13C NMR (75 MHz, CDCl3):
δ = 35.5 (NCH3), 110.9 (C-3), 117.9 (C-8), 122.0 (C-α), 124.0 (C-
β), 124.1 (C-4a), 125.0 (C-6), 125.7 (C-5), 126.1 (C-1), 129.5 (C-
2,6), 129.6 (C-3,5), 130.2 (C-4), 133.6 (C-7), 137.0 (C-4),
141.3 (C-5), 155.9 (C-8a), 161.4 (C-2), 178.5 (C-4) ppm. (E)-2-[2-
(1-Methyl-4-phenyl-1H-1,2,3-triazol-5-yl)vinyl]-4H-chromen-4-one
(11a): 1H NMR (500 MHz, CDCl3): δ = 4.27 (s, 3 H, NCH3), 6.27
(s, 1 H, 3-H) ppm.
(E)-2-{2-[2-Methyl-4-(4-methylphenyl)-2H-1,2,3-triazol-5-yl]vinyl}-
4H-chromen-4-one (9b): Yield 257 mg (75%), m.p. 192–194 °C. 1H
NMR (300 MHz, CDCl3): δ = 2.46 (s, 3 H, CH3), 4.29 (s, 3 H, N-
CH3), 6.49 (s, 1 H, 3-H), 7.13, (d, J = 15.8 Hz, 1 H, α-H), 7.34 (d,
J = 8.0 Hz, 2 H, 3,5-H), 7.42 (ddd, J = 7.7, 7.4, 1.1 Hz, 1 H, 6-
H), 7.50 (dd, J = 8.4, 1.1 Hz, 1 H, 8-H), 7.55 (d, J = 8.0 Hz, 2 H,
2,6-H), 7.64 (d, J = 15.8 Hz, 1 H, β-H), 7.70 (ddd, J = 8.4, 7.4,
1.6 Hz, 1 H, 7-H), 8.21 (dd, J = 7.7, 1.6 Hz, 1 H, 5-H) ppm. 13C
NMR (75 MHz, CDCl3): δ = 21.4 (CH3), 42.2 (NCH3), 110.8 (C-
3), 118.0 (C-8), 122.7 (C-α), 123.6 (C-4a), 124.9 (C-β), 125.3 (C-6),
125.7 (C-5), 127.1 (C-1), 128.2 (C-2,6), 129.8 (C-3,5), 134.1
(C-7), 139.1 (C-4), 140.3 (C-5), 147.7 (C-4), 156.0 (C-8a), 161.9
(C-2), 178.5 (C-4) ppm. HRMS (ESI+): m/z calcd. for C21H18N3O2
[M + H]+ 344.1399, found 344.1381. MS (ESI+): m/z (%) = 344
(100) [M + H]+, 687 (11) [2M + H]+.
Mixture of 10b and 11b (81:19): Yield 86 mg (25%). (E)-2-{2-[3-
Methyl-4-(4-methylphenyl)-1H-1,2,3-triazol-5-yl]vinyl}-4H-
chromen-4-one (10b): 1H NMR (300 MHz, CDCl3): δ = 2.51 (s, 3
H, CH3), 4.01 (s, 3 H, NCH3), 6.31 (s, 1 H, 3-H), 7.20 (d, J =
15.9 Hz, 1 H, α-H), 7.30 (d, J = 8.1 Hz, 2 H, 2,6-H), 7.32–7.38
(m, 1 H, 6-H), 7.37 (d, J = 15.9 Hz, 1 H, β-H), 7.41–7.45 (m, 3 H,
8-H, 3,5-H), 7.64 (ddd, J = 8.5, 7.1, 1.6 Hz, 1 H, 7-H), 8.17 (dd,
J = 7.9, 1.6 Hz, 1 H, 5-H) ppm. 13C NMR (75 MHz, CDCl3): δ =
21.5 (CH3), 35.5 (NCH3), 110.8 (C-3), 117.9 (C-8), 121.8 (C-α),
123.0 (C-4a), 124.0 (C-1), 124.3 (C-β), 125.0 (C-6), 125.7 (C-5),
129.4 (C-2,6), 130.2 (C-3,5), 133.7 (C-7), 137.2 (C-4), 140.6
(C-4), 141.1 (C-5), 155.9 (C-8a), 161.6 (C-2), 178.5 (C-4) ppm.
(E)-2-{2-[1-Methyl-4-(4-methylphenyl)-1H-1,2,3-triazol-5-yl]vinyl}-
4H-chromen-4-one (11b): 1H NMR (300 MHz, CDCl3): δ = 2.2 (s,
3 H, CH3), 3.97 (s, 3 H, NCH3), 6.40 (s, 1 H, 3-H) ppm.
(E)-2-{2-[4-(4-Methoxyphenyl)-2-methyl-2H-1,2,3-triazol-5-
yl]vinyl}-4H-chromen-4-one (9c): Yield 280 mg (78%), m.p. 186–
187 °C. 1H NMR (300 MHz, CDCl3): δ = 3.90 (s, 3 H, OCH3),
4.28 (s, 3 H, NCH3), 6.34 (s, 1 H, 3-H), 7.06 (d, J = 8.8 Hz, 2 H,
3,5-H), 7.10 (d, J = 15.8 Hz, 1 H, α-H), 7.40 (ddd, J = 7.7, 7.3,
1.1 Hz, 1 H, 6-H), 7.48 (d, J = 8.2 Hz, 1 H, 8-H), 7.59 (d, J =
15.8 Hz, 1 H, β-H), 7.59 (d, J = 8.8 Hz, 2 H, 2,6-H), 7.67 (ddd,
J = 8.2, 7.3, 1.6 Hz, 1 H, 7-H), 8.20 (dd, J = 7.7, 1.6 Hz, 1 H, 5-
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 42.1 (NCH3), 55.4
(OCH3), 111.1 (C-3), 114.4 (C-3,5), 117.9 (C-8), 122.5 (C-1),
122.9 (C-α), 124.1 (C-4a), 124.2 (C-β), 125.0 (C-6), 125.7 (C-5),
129.6 (C-2,6), 133.7 (C-7), 140.2 (C-5), 147.3 (C-4), 155.9 (C-
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8a), 160.2 (C-4), 161.1 (C-2), 178.5 (C-4) ppm. HRMS (ESI+):
m/z calcd. for C21H18N3O3 [M + H]+ 360.1348, found 360.1332.
MS (ESI+): m/z (%) = 344 (4) [M – CH3]+, 360 (100) [M + H]+,
719 (10) [2M + H]+.
Mixture of 10c and 11c (87:13): Yield 79 mg (22%). (E)-2-{2-[4-(4-
Methoxyphenyl)-3-methyl-1H-1,2,3-triazol-5-yl]vinyl}-4H-chromen-
4-one (10c): 1H NMR (300 MHz, CDCl3): δ = 3.94 (s, 3 H, OCH3),
4.00 (s, 3 H, NCH3), 6.30 (s, 1 H, 3-H), 7.13 (d, J = 8.8 Hz, 2 H,
3,5-H), 7.19 (d, J = 15.9 Hz, 1 H, α-H), 7.33–7.40 (m, 4 H, β-
H, 6-H, 2,6-H), 7.43 (dd, J = 8.5, 0.6 Hz, 1 H, 8-H), 7.64 (ddd,
J = 8.5, 7.0, 1.6 Hz, 1 H, 7-H), 8.16 (dd, J = 7.9, 1.6 Hz, 1 H, 5-
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 35.4 (NCH3), 55.5
(OCH3), 110.8 (C-3), 115.0 (C-3,5), 117.9 (C-8), 121.6 (C-α),
124.1 (C-1), 124.3 (C-β), 125.0 (C-6), 125.7 (C-5), 130.9 (C-
2,6), 133.6 (C-7), 137.0 (C-4), 141.2 (C-5), 155.9 (C-8a), 161.0
(C-4), 161.5 (C-2), 178.5 (C-4) ppm. (E)-2-{2-[4-(4-Meth-
oxyphenyl)-1-methyl-1H-1,2,3-triazol-5-yl]vinyl}-4H-chromen-4-one
(11c): 1H NMR (300 MHz, CDCl3): δ = 3.88 (s, 3 H, OCH3), 4.25
(s, 3 H, NCH3), 6.27 (s, 1 H, 3-H) ppm.
(E)-2-{2-[4-(4-Bromophenyl)-2-methyl-2H-1,2,3-triazol-5-yl]vinyl}-
4H-chromen-4-one (9d): Yield 335 mg (82%), m.p. 223–224 °C. 1H
NMR (300 MHz, CDCl3): δ = 4.29 (s, 3 H, NCH3), 6.50 (s, 1 H,
3-H), 7.15 (d, J = 15.8 Hz, 1 H, α-H), 7.43 (dt, J = 7.7, 0.8 Hz, 1
H, 6-H), 7.52 (dd, J = 7.6, 0.8 Hz, 1 H, 8-H), 7.54 (d, J = 8.5 Hz,
2 H, 2,6-H), 7.58 (d, J = 15.8 Hz, 1 H, β-H), 7.67 (d, J = 8.5 Hz,
2 H, 3,5-H), 7.68–7.74 (m, 1 H, 7-H), 8.21 (dd, J = 7.7, 1.6 Hz,
1 H, 5-H) ppm. 13C NMR (75 MHz, CDCl3): δ = 42.2 (NCH3),
111.1 (C-3), 117.9 (C-8), 123.3 (C-4), 123.5 (C-β), 123.7 (C-α),
124.1 (C-4a), 125.2 (C-6), 125.7 (C-5), 129.1 (C-1), 129.8 (C-
2,6), 132.2 (C-3,5), 133.9 (C-7), 140.5 (C-5), 146.3 (C-4),
155.9 (C-8a), 160.9 (C-2), 178.5 (C-4) ppm. HRMS (ESI+): m/z
calcd. for C20H1579BrN3O2 [M + H]+ 408.0348, found 408.0330;
calcd. for C20H1581BrN3O2 [M + H]+ 410.0327, found 410.0306.
MS (ESI+): m/z (%) = 408 (100) [M + H]+, 430 (15) [M + Na]+.
Mixture of 10d and 11d (93:7): Yield 73 mg (18%). (E)-2-{2-[4-(4-
Bromophenyl)-1-methyl-1H-1,2,3-triazol-5-yl]vinyl}-4H-chromen-4-
one (10d): 1H NMR (500 MHz, CDCl3): δ = 4.02 (s, 3 H, NCH3),
6.33 (s, 1 H, 3-H), 7.26–7.31 (m, 2 H, α-H, β-H), 7.30 (d, J =
8.5 Hz, 2 H, 2,6-H), 7.38 (ddd, J = 7.9, 7.1, 0.7 Hz, 1 H, 6-H),
7.45 (dd, J = 8.5, 0.7 Hz, 1 H, 8-H), 7.65 (ddd, J = 8.5, 7.1, 1.6 Hz,
1 H, 7-H), 7.77 (d, J = 8.5 Hz, 2 H, 3,5-H), 8.18 (dd, J = 7.9,
1.6 Hz, 1 H, 5-H) ppm. 13C NMR (125 MHz, CDCl3): δ = 35.5
(NCH3), 111.2 (C-3), 117.9 (C-8), 122.5 (C-β), 123.3 (C-α), 124.1
(C-4a), 124.9 and 125.0 (C-1 and C-4), 125.1 (C-6), 125.7 (C-5),
131.1 (C-2,6), 132.9 (C-3,5), 133.7 (C-7), 135.9 (C-4), 141.5
(C-5), 155.9 (C-8a), 161.2 (C-2), 178.4 (C-4) ppm. (E)-2-{2-[4-(4-
Bromophenyl)-3-methyl-1H-1,2,3-triazol-5-yl]vinyl}-4H-chromen-4-
one (11d): 1H NMR (500 MHz, CDCl3): δ = 4.03 (s, 3 H, NCH3),
6.30 (s, 1 H, 3-H) ppm.
General Procedure for the Synthesis of 4-(4-Aryl-2-methyl-2H-1,2,3-
triazol-5-yl)-2-methyl-3a,4,5,11b-tetrahydrochromeno[3,2-e]isoind-
ole-1,3,11(2H)-triones (12a–d). Method A: N-Methylmaleimide
(0.10 g, 0.92 mmol) was added to a solution of the appropriate (E)-
2-[2-(4-aryl-2-methyl-2H-1,2,3-triazol-5-yl)vinyl]-4H-chromen-4-
ones 9a–d (0.18 mmol) in dry DMF (5 μL). The mixture was heated
at 160 °C under microwave irradiation (multimode apparatus) for
20 min. The residue was dissolved in CH2Cl2 and purified by pre-
parative TLC using CH2Cl2/EtOAc (4:1) as eluent to give desired
cycloadducts 12a–d in the following yields: 12a (29.3 mg, 37%), 12b
(27.0 mg, 33%), 12c (33.9 mg, 40%), 12d (28.0 mg, 30%).
Method B: N-Methylmaleimide (0.10 g, 0.92 mmol) was mixed with
the appropriate (E)-2-[2-(4-aryl-2-methyl-2H-1,2,3-triazol-5-yl)
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vinyl]-4H-chromen-4-ones 9a–d (0.18 mmol) in a close vessel. The
mixture was heated at 200 °C under microwave irradiation (mono-
mode apparatus) for 10 min. The residue was dissolved in CH2Cl2
and purified by preparative TLC using CH2Cl2/EtOAc (4:1) as elu-
ent to give desired cycloadducts 12a–d in the following yields: 12a
(28.5 mg, 36%), 12b (39.3 mg, 48%), 12c (33.9 mg, 40%), 12d
(35.5 mg, 38%).
2-Methyl-4-(2-methyl-4-phenyl-2H-1,2,3-triazol-5-yl)-3a,4,5,11b-
tetrahydrochromeno[3,2-e]isoindole-1,3,11(2H)-trione (12a): M.p.
152–153 °C. 1H NMR (300 MHz, CDCl3): δ = 2.82 (s, 3 H, 2-
NCH3), 2.98–3.24 (m, 2 H, 5-H), 3.47 (dd, J = 8.8, 6.4 Hz, 1 H,
3a-H), 3.84–3.91 (m, 1 H, 4-H), 4.18 (s, 3 H, 2-NCH3), 4.64 (d, J
= 8.8 Hz, 1 H, 11b-H), 7.40–7.49 (m, 5 H, 7-H, 9-H, 3,4,5-H),
7.61 (dd, J = 8.1, 1.5 Hz, 2 H, 2,6-H), 7.67 (ddd, J = 8.5, 7.1,
1.6 Hz, 1 H, 8-H), 8.30 (dd, J = 8.4, 1.6 Hz, 1 H, 10-H) ppm. 13C
NMR (75 MHz, CDCl3): δ = 24.9 (2-NCH3), 30.6 (C-5), 32.4 (C-
4), 37.9 (C-11b), 41.2 (C-3a), 41.7 (2-NCH3), 113.3 (C-11a), 117.7
(C-7), 123.7 (C-10a), 125.3 (C-9), 126.4 (C-10), 127.7 (C-2,6),
128.6 (C-4), 129.0 (C-3,5), 130.9 (C-1), 133.7 (C-8), 142.3 (C-
5), 145.1 (C-4), 155.7 (C-6a), 164.1 (C-5a), 174.7 (C-3), 175.2 (C-
1), 176.1 (C-11) ppm. HRMS (ESI+): m/z calcd. for C25H21N4O4
[M + H]+ 441.1563, found 441.1539. MS (ESI+): m/z (%) = 441
(100) [M + H]+, 463 (17) [M + Na]+, 479 (10) [M + K]+.
2-Methyl-4-[2-methyl-4-(4-methylphenyl)-2H-1,2,3-triazol-5-yl]-
3a,4,5,11b-tetrahydrochromeno[3,2-e]isoindole-1,3,11(2H)-trione
(12b): M.p. 143–145 °C. 1H NMR (300 MHz, CDCl3): δ = 2.40 (s,
3 H, CH3), 2.82 (s, 3 H, 2-NCH3), 2.98–3.24 (m, 2 H, 5-H), 3.48
(dd, J = 8.8, 6.4 Hz, 1 H, 3a-H), 3.82–3.89 (m, 1 H, 4-H), 4.17 (s,
3 H, 2-NCH3), 4.63 (d, J = 8.8 Hz, 1 H, 11b-H), 7.26 (d, J =
8.0 Hz, 2 H, 3,5-H), 7.40–7.45 (m, 1 H, 9-H), 7.41 (d, J =
8.2 Hz, 1 H, 7-H), 7.49 (d, J = 8.0 Hz, 2 H, 2,6-H), 7.67 (ddd,
J = 8.2, 7.2, 1.5 Hz, 1 H, 8-H), 8.29 (dd, J = 8.2, 1.5 Hz, 1 H, 10-
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 21.3 (CH3), 24.9 (2-
NCH3), 30.5 (C-5), 32.4 (C-4), 37.9 (C-11b), 41.1 (C-3a), 41.7 (2-
NCH3), 113.3 (C-11a), 117.7 (C-7), 123.7 (C-10a), 125.3 (C-9),
126.4 (C-10), 127.5 (C-2,6), 127.9 (C-1), 129.7 (C-3,5),
133.7 (C-8), 138.6 (C-4), 142.2 (C-5), 145.1 (C-4), 155.7 (C-6a),
164.2 (C-5a), 174.8 (C-3), 175.2 (C-1), 176.0 (C-11) ppm. HRMS
(ESI+): m/z calcd. for C26H23N4O4 [M + H]+ 455.1719, found
455.1699. MS (ESI+): m/z (%) = 455 (100) [M + H]+, 477 (26) [M
+ Na]+.
4-[4-(4-Methoxyphenyl)-2-methyl-2H-1,2,3-triazol-5-yl]-2-methyl-
3a,4,5,11b-tetrahydrochromeno[3,2-e]isoindole-1,3,11(2H)-trione
(12c): M.p. 167–169 °C. 1H NMR (300 MHz, CDCl3): δ = 2.82 (s,
3 H, 2-NCH3), 2.97–3.23 (m, 2 H, 5-H), 3.48 (dd, J = 8.8, 6.4 Hz,
1 H, 3a-H), 3.79–3.90 (m, 1 H, 4-H), 3.85 (s, 3 H, OCH3), 4.16 (s,
3 H, 2-NCH3), 4.64 (d, J = 8.8 Hz, 1 H, 11b-H), 6.98 (d, J =
8.8 Hz, 2 H, 3,5-H), 7.41 (d, J = 8.2 Hz, 1 H, 7-H), 7.40–7.45
(m, 1 H, 9-H), 7.53 (d, J = 8.8 Hz, 2 H, 2,6-H), 7.67 (ddd, J =
8.2, 7.1, 1.6 Hz, 1 H, 8-H), 8.29 (dd, J = 8.4, 1.6 Hz, 1 H, 10-
H) ppm. 13C NMR (75 MHz, CDCl3): δ = 24.9 (2-NCH3), 30.6
(C-5), 32.4 (C-4), 37.9 (C-11b), 41.2 (C-3a), 41.7 (2-NCH3), 55.3
(OCH3), 113.3 (C-11a), 114.4 (C-3,5), 117.7 (C-7), 123.2 (C-1),
123.6 (C-10a), 125.3 (C-9), 126.4 (C-10), 129.0 (C-2,6), 133.7
(C-8), 142.0 (C-4), 145.0 (C-5), 155.7 (C-6a), 159.9 (C-4), 164.1
(C-5a), 174.7 (C-3), 175.2 (C-1), 176.0 (C-11) ppm. HRMS (ESI+):
m/z calcd. for C26H23N4O5 [M + H]+ 471.1668, found 471.1645.
MS (ESI+): m/z (%) = 471 (100) [M + H]+, 493 (8) [M + Na]+.
4-[4-(4-Bromophenyl)-2-methyl-2H-1,2,3-triazol-5-yl]-2-methyl-
3a,4,5,11b-tetrahydrochromeno[3,2-e]isoindole-1,3,11(2H)-trione
(12d): M.p. 145–146 °C. 1H NMR (300 MHz, CDCl3): δ = 2.81 (s,
3 H, 2-NCH3), 2.96–3.24 (m, 2 H, 5-H), 3.46 (dd, J = 8.8, 6.4 Hz,
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1 H, 3a-H), 3.82–3.88 (m, 1 H, 4-H), 4.16 (s, 3 H, 2-NCH3), 4.64
(d, J = 8.8 Hz, 1 H, 11b-H), 7.40–7.45 (m, 1 H, 9-H), 7.41 (d, J =
8.1 Hz, 1 H, 7-H), 7.49 (d, J = 8.6 Hz, 2 H, 2,6-H), 7.59 (d, J
= 8.6 Hz, 2 H, 3,5-H), 7.67 (ddd, J = 8.1, 7.2, 1.6 Hz, 1 H, 8-
H), 8.29 (dd, J = 8.2, 1.6 Hz, 1 H, 10-H) ppm. 13C NMR (75 MHz,
CDCl3): δ = 24.9 (2-NCH3), 30.7 (C-5), 32.3 (C-4), 37.9 (C-11b),
41.2 (C-3a), 41.8 (2-NCH3), 113.3 (C-11a), 117.7 (C-7), 122.9 (C-
4), 123.6 (C-10a), 125.4 (C-9), 126.4 (C-10), 129.3 (C-2,6),
129.8 (C-1), 132.2 (C-3,5), 133.8 (C-8), 142.4 (C-5), 144.1 (C-
4), 155.7 (C-6a), 163.8 (C-5a), 174.6 (C-3), 175.2 (C-1), 175.9 (C-
11) ppm. HRMS (ESI+): m/z calcd. for C25H2079BrN4O4 [M +
H]+ 519.0668, found 519.0649; calcd. for C25H2081BrN4O4 [M + H]
+ 521.0647, found 521.0627. MS (ESI+): m/z (%) = 519 (20) [M +
H]+, 541 (15) [M + Na]+.
General Procedure for the Synthesis of 4-(5-Aryl-2-methyl-2H-1,2,3-
triazol-4-yl)-2-methylchromeno[3,2-e]isoindole-1,3,11(2H)-trione
(13a–d): 2,3-Dichloro-5,6-dicyanobenzoquinone (DDQ) (121 mg,
534 μmol) was added to a solution of the appropriate 4-(4-aryl-2-
methyl-2H-1,2,3-triazol-5-yl)-2-methyl-3a,4,5,11b-tetrahydro-
chromeno[3,2-e]isoindole-1,3,11(2H)-triones 12a–d (178 μmol) in
toluene (10 mL). The mixture was stirred at 100 °C for 1 h. After
that period, the solvent was evaporated to dryness. The residue was
purified by preparative TLC using CH2Cl2 as eluent to give desired
4-(4-aryl-2-methyl-2H-1,2,3-triazol-5-yl)-2-methylchromeno[3,2-e]-
isoindole-1,3,11(2H)-triones 13a–d in good yields (57–80%).
2-Methyl-4-(2-methyl-4-phenyl-2H-1,2,3-triazol-5-yl)chromeno-
[3,2-e]isoindole-1,3,11(2H)-trione (13a): Yield 57.5 mg (74%), m.p.
310–312 °C. 1H NMR (300 MHz, CDCl3): δ = 3.07 (s, 3 H, 2-
NCH3), 4.35 (s, 3 H, 2-NCH3), 7.28–7.31 (m, 3 H, 3,4,5-H),
7.39–7.43 (m, 2 H, 2,6-H), 7.44–7.49 (m, 1 H, 9-H), 7.50 (d, J
= 7.3 Hz, 1 H, 7-H), 7.78 (ddd, J = 8.6, 7.3, 1.6 Hz, 1 H, 8-H),
7.85 (s, 1 H, 5-H), 8.40 (dd, J = 8.0, 1.6 Hz, 1 H, 10-H) ppm. 13C
NMR (75 MHz, CDCl3): δ = 24.4 (2-NCH3), 42.1 (2-NCH3),
117.6 (C-7), 119.7 (C-11a), 123.0 (C-10a), 125.2 (C-9), 126.3 (C-5),
127.0 (C-2,6), 127.4 (C-3a), 127.5 (C-10), 128.5 (C-4), 128.8
(C-3,5), 130.3 (C-1), 134.1 and 134.2 (C-4 and C-11b), 135.5
(C-8), 138.7 (C-5), 146.5 (C-4), 155.0 (C-6a), 159.7 (C-5a), 164.4
and 165.4 (C-1 and C-3), 174.3 (C-11) ppm. HRMS (ESI+): m/z
calcd. for C25H17N4O4 [M + H]+ 437.1250, found 437.1229. MS
(ESI+): m/z (%) = 895 (100) [M + Na]+, 437 (88) [M + H]+, 911
(35) [2M + K]+.
2-Methyl-4-[2-methyl-4-(4-methylphenyl)-2H-1,2,3-triazol-5-yl]-
chromeno[3,2-e]isoindole-1,3,11(2H)-trione (13b): Yield 64.1 mg
(80%), m.p. 302–303 °C. 1H NMR (300 MHz, CDCl3): δ = 2.31 (s,
3 H, CH3), 3.08 (s, 3 H, 2-NCH3), 4.34 (s, 3 H, 2-NCH3), 7.09 (d,
J = 8.1 Hz, 2 H, 3,5-H), 7.29 (d, J = 8.1 Hz, 2 H, 2,6-H),
7.44–7.49 (m, 1 H, 9-H), 7.50 (d, J = 7.3 Hz, 1 H, 7-H), 7.78 (ddd,
J = 8.5, 7.3, 1.6 Hz, 1 H, 8-H), 7.83 (s, 1 H, 5-H), 8.39 (dd, J =
8.0, 1.6 Hz, 1 H, 10-H) ppm. 13C NMR (126 MHz, CDCl3): δ =
21.3 (CH3), 24.4 (2-NCH3), 42.1 (2-NCH3), 117.6 (C-7), 119.7 (C-
11a), 123.0 (C-10a), 125.2 (C-9), 126.4 (C-5), 126.9 (C-2,6),
127.4 (C-3a), 127.5 (C-10), 129.5 (C-3,5), 134.1 and 134.4 (C-
11b and C-4), 135.5 (C-8), 138.4 (C-5), 138.5 (C-1, C-4), 146.5
(C-4), 155.0 (C-6a), 159.7 (C-5a), 164.3 and 165.5 (C-1 and C-3),
174.2 (C-11) ppm. HRMS (ESI+): m/z calcd. for C26H19N4O4 [M
+ H]+ 451.1406, found 451.1382. MS (ESI+): m/z (%) = 451 (100)
[M + H]+, 489 (63) [M + K]+, 923 (16) [2M + Na]+, 939 (20) [2M
+ K]+.
4-[4-(4-Methoxyphenyl)-2-methyl-2H-1,2,3-triazol-5-yl]-2-methyl-
chromeno[3,2-e]isoindole-1,3,11(2H)-trione (13c): Yield 68.9 mg
(83%), m.p. 286–288 °C. 1H NMR (500 MHz, CDCl3): δ = 3.09 (s,
3 H, 2-NCH3), 3.78 (s, 3 H, OCH3), 4.33 (s, 3 H, 2-NCH3), 6.81
(E)-2-(4-Arylbut-1-en-3-yn-1-yl)chromones as Synthons
(d, J = 8.9 Hz, 2 H, 3,5-H), 7.34 (d, J = 8.9 Hz, 2 H, 2,6-H),
7.46 (ddd, J = 8.0, 7.1, 0.7 Hz, 1 H, 9-H), 7.50 (dd, J = 8.3, 0.7 Hz,
1 H, 7-H), 7.78 (ddd, J = 8.3, 7.1, 1.6 Hz, 1 H, 8-H), 7.84 (s, 1 H,
5-H), 8.40 (dd, J = 8.0, 1.6 Hz, 1 H, 10-H) ppm. 13C NMR
(126 MHz, CDCl3): δ = 24.4 (2-NCH3), 42.1 (2-NCH3), 55.3
(OCH3), 114.3 (C-3,5), 117.6 (C-7), 119.6 (C-11a), 122.8 (C-1),
123.0 (C-10a), 125.2 (C-9), 126.4 (C-5), 127.4 (C-3a), 127.5 (C-10),
128.3 (C-2,6), 134.1 and 134.4 (C-4 and C-11b), 135.5 (C-8),
138.1 (C-5), 146.3 (C-4), 155.0 (C-6a), 159.76 (C-4), 159.75 (C-
5a), 164.3 and 165.4 (C-1 and C-3), 174.3 (C-11) ppm. HRMS
(ESI+): m/z calcd. for C26H19N4O5 [M + H]+ 467.1355, found
467.1332. MS (ESI+): m/z (%) = 467 (100) [M + H]+, 489 (27) [M
+ Na]+, 505 (20) [M + K]+.
4-[4-(4-Bromophenyl)-2-methyl-2H-1,2,3-triazol-5-yl]-2-methyl-
chromeno[3,2-e]isoindole-1,3,11(2H)-trione (13d): Yield 52.3 mg
(57%), m.p. 312–313 °C. 1H NMR (500 MHz, CDCl3): δ = 3.09 (s,
3 H, 2-NCH3), 4.34 (s, 3 H, 2-NCH3), 7.29 (d, J = 8.6 Hz, 2 H,
2,6-H), 7.42 (d, J = 8.6 Hz, 2 H, 3,5-H), 7.47 (ddd, J = 8.0,
7.1, 0.7 Hz, 1 H, 9-H), 7.51 (dd, J = 8.3, 0.7 Hz, 1 H, 7-H), 7.79
(ddd, J = 8.3, 7.1, 1.6 Hz, 1 H, 8-H), 7.84 (s, 1 H, 5-H), 8.40 (dd,
J = 8.0, 1.6 Hz, 1 H, 10-H) ppm. 13C NMR (126 MHz, CDCl3): δ
= 24.5 (2-NCH3), 42.2 (2-NCH3), 117.6 (C-7), 119.8 (C-11a), 122.7
(C-4), 123.0 (C-10a), 125.3 (C-9), 126.3 (C-5), 127.2 (C-3a), 127.5
(C-10), 128.4 (C-2,6), 129.4 (C-1), 132.0 (C-3,5), 133.8 and
134.1 (C-4 and C-11b), 135.6 (C-8), 138.7 (C-5), 145.5 (C-4),
155.0 (C-6a), 159.8 (C-5a), 164.1 and 165.4 (C-1 and C-3), 174.1
(C-11) ppm. HRMS (ESI+): m/z calcd. for C25H1679BrN4O4 [M +
H]+ 515.0355, found 515.0330; calcd. for C25H1681BrN4O4 [M +
H]+ 517.0334, found 517.0484. MS (ESI+): m/z (%) = 515 (15) [M
+ H]+, 537 (24) [M + Na]+, 555 (21) [M + K]+.
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